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I 
The resurrection of inactive endogenous retroviruses allows us to learn about 
interactions between extinct pathogens and their hosts that occurred millions of years 
ago.  Two of these paleoviruses, chimpanzee endogenous retrovirus 1 and 2 (CERV1 and 
CERV2), are relatives of modern murine leukemia viruses that are found in the genomes 
of a variety of old world primates, but are absent from the human genome.  The non-
existence of human CERV1 and CERV2 homologues is peculiar given the numerous 
apparent cross-species transmissions that occurred between ancestors of old world 
monkeys, gorillas, and chimpanzees.  It is possible that antiviral proteins were able to 
protect human ancestors from colonization by CERV1 and CERV2.  Indeed, sequence 
analyses of modern primate restriction factors has suggested that these genes have 
evolved under positive selection, presumably due to their combat with invading 
pathogens throughout primate history.  Here we investigate whether TRIM5 and 
APOBEC3 antiviral factors were able to restrict the replication of CERV1 and CERV2.  
Such an interaction would imply a potential involvement of these proteins in the limited 
host range and, perhaps, even the extinction of CERV1 and CERV2.  Reciprocally, 
activity against CERV1 and CERV2 would suggest that archaic gammaretroviruses 
contributed to the positive selection observed in TRIM5 and APOBEC3 genes.  
Our analyses suggest that TRIM5" proteins did not pose a major barrier to the 
cross-species transmission or contributed to the extinction of CERV1 and CERV2.  
However, we uncovered extensive evidence for the inactivation of endogenous 
gammaretroviruses by the action of APOBEC3 cytidine deaminases.  Both CERV1 and 
CERV2, as well as their homologues in the rhesus macaque, bore mutational scars that 
are characteristic of APOBEC3 activity.  A reconstructed CERV2 Gag was used in vitro 
to confirm that APOBEC3G was capable of restricting CERV2 infection.  Therefore, it 
appears that primate APOBEC3 proteins were capable of targeting ancient primate 
gammaretroviruses.  It remains possible that APOBEC3 proteins were able to limit the 
cross-species transmission and cause the inactivation of these viruses. 
 
II  
Although HIV-1 is able to use an antagonist to defend itself from restriction by 
APOBEC3 proteins, hypermutation is abundant in vivo.  It is currently unclear if 
hypermutants have an impact on the evolution of a viral population.  The diversity 
induced by APOBEC3 may benefit a continually evolving population by providing a 
large scope of variability for selection to act upon or, quite the opposite, it may constitute 
a deleterious genetic load.  The potential impact that APOBEC3-induced hypermutation 
can have on a replicating HIV-1 population was studied in vitro.  After a period of 
growth in T cell lines, an accumulation of hypermutated sequences was observed in an 
HIV-1 that lacked the APOBEC3 antagonist, Vif.  The resulting viral population 
displayed a fitness disadvantage in non-restrictive cells relative to a Vif-proficient virus.  
In spite of this apparent genetic load, though, the Vif-deficient virus was capable of 
persistent replication.  However, unlike the Vif-positive virus, the hypermutated virus 
was unable to acquire drug resistance in the presence of nevirapine.  Although this result 
argues against the notion that APOBEC3-induced variability can accelerate HIV-1 
evolution, a small degree of APOBEC3-associated mutations also occurred in the Vif-
proficient virus and this low-level APOBEC3 activity may have contributed to the 
emergence of nevirapine resistance.    
 
III  
In order to enter cells, retroviruses must usurp a host cell surface receptor.  Viral 
receptors can dictate both the cell tropism and host range of the retroviruses that exploit 
them.  Therefore, the identity of the CERV2 receptor is critical to the study of CERV2 
transmissions and endogenizations that took place during ancient primate evolution.  To 
investigate the CERV2 host range and identify its receptor, we constructed a consensus 
CERV2 envelope protein derived using sequences found in the chimpanzee genome.  
CERV2 enveloped MLV particles were capable of infecting cell lines from a wide range 
of species, including humans. The permissivity of human cells for CERV2 argues against 
the notion that human ancestors were protected from CERV2 by the lack of a functional 
receptor.  Using a Hela cDNA library expressed in CERV2 resistant hamster cells, we 
identified copper transport protein 1 (CTR1) as a novel retrovirus receptor that was 
presumably used by CERV2 during its exogenous replication more than one million years 
ago.  Expression of human CTR1 was sufficient to confer CERV2 permissively to 
otherwise resistant hamster cell lines, which was accompanied by an increase in virion 
binding.  The observed increase in hamster cell infection that came with CTR1 
expression was specific to CERV2 enveloped virus, with no gain in permissivity to 
pseudotypes bearing envelopes from several other gammaretroviruses.  Furthermore, 
siRNA-induced CTR1 knockdown or CuCl2 treatment specifically decreased CERV2 
infection of human cells.  We have also identified mutations in highly conserved CTR1 
residues that have rendered hamster CTR1 inactive as a CERV2 cell surface receptor, 
including a deletion in a copper-binding motif that is largely conserved from humans to 
zebrafish.  These receptor-inactivating mutations in hamster CTR1 are accompanied by 
an increased number of extracellular copper-coordinating residues compared to CTR1 
proteins from other species.  This apparent compensation may represent an evolutionary 
barrier that primates would have had to overcome to avoid CTR1 usage by CERV2 or 
related viruses that might have used this protein as a receptor. 
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Chapter I.  Retroviridae, host proteins, and endogenous retroviruses 
 
 
 The two processes that define retroviruses are the synthesis of a DNA 
intermediate from two single stranded RNA genomes, and the subsequent integration of 
the viral genome into host chromosomal DNA (1).  The presence of provirus in cellular 
genomes of the host means that the viral genome will be copied by cellular DNA 
replication machinery and then carried forward into progeny cells.  The long-term 
residence of human immunodeficiency virus (HIV) in target cells, including long-lived 
resting CD4+ T cells, is likely to be a primary reason why patients are unable to clear the 
virus even during highly active antiretroviral therapy (2-4).  Retroviral integration into 
the genomes of target cells also allows for the possibility of Mendelian inheritance of 
proviruses if their integration occurs in the host germ line (5).  This route of vertical 
transmission results in an organism-wide establishment of provirus in the genome of 
progeny.  Such endogenization events have occurred numerous times during primate 
evolution and, in some cases, are shared by diverse primate lineages (6-12).  Endogenous 
retroviruses thus represent a record of ancient retroviral infections and these paleoviruses 
can provide us with information regarding past interactions of hosts and pathogens (13). 
 Retroviruses are categorized into several genera based on their phylogenetic 
relatedness (Figure 1).  The lentiviruses include HIV and the simian immunodeficiency 
viruses (SIV).  At least three transmissions of an SIV from chimpanzees (SIVcpz) 
resulted in HIV-1; a pathogen whose infection causes acquired immunodeficiency 
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syndrome (AIDS) and, according to the World Health Organization, has spread to more 
than 60 million people worldwide (14, 15).  Lentiviruses are complex retroviruses in that 
they encode several small accessory genes in addition to the GagPol and Env genes 
common to all retroviruses.  In contrast, the lack of accessory genes in 
gammaretroviruses classifies them as simple retroviruses.  The gammaretrovirus genus 
includes the murine leukemia viruses (MLV), feline leukemia virus (FeLV), and gibbon 
ape leukemia virus (GALV).   
 
Figure 1. Phylogeny of retroviruses.  An Unrooted neighbor-joining tree based on an alignment of 
reverse transcriptase amino acid sequences is shown.  Adapted from Weiss Retrovirology 2006 
(16). 
 
 Lentiviruses have rarely been observed to be endogenous in their hosts.  The only 
known endogenous lentiviruses were identified in the genomes of the European rabbit 
and the gray mouse lemur of Madagascar (17, 18).  A phylogeny of reverse transcriptase 
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sequences and the presence of the Tat and Rev accessory genes suggest that the rabbit 
endogenous lentivirus (RELIK) constitutes a unique lentivirus subgroup.  The existence 
of orthologous RELIK insertions in the European hare suggests that these viruses 
replicated before the divergence of the European hare and rabbit from a common ancestor 
12 million years ago (19).  Phylogenetic analyses using conserved portions of lentiviral 
GagPol grouped the gray mouse lemur endogenous lentivirus with the modern primate 
lentiviruses and it was suggested that this virus represents an evolutionary intermediate 
between the SIVs and ancestral lentiviruses.  Importantly, the identification of an SIV in 
the lemur suggests that either primate lentiviruses were able to spread in a vector species 
capable of traversing water, or primate lentiviruses are as old as the last colonization of 
Madagascar by terrestrial mammals 14 million years ago.  
 Unlike lentiviruses, endogenous gammaretroviruses are common in diverse 
mammalian species and these viruses include the porcine endogenous retroviruses 
(PERV), feline endogenous retroviruses (RD114 and endogenous FeLV), and a variety of 
endogenous MLVs (all discussed in later sections).  Gammaretroviruses are also 
abundant in primate genomes and, among them, chimpanzee endogenous retroviruses 1 
and 2 (CERV1 and CERV2) are the groups most closely related to the modern murine 
leukemia virus (8, 9, 20).  CERV1 and 2 are of particular interest because, in spite of the 
existence of homologues in the genomes of bonobos, gorillas, and old world monkeys, 
they are curiously absent in humans.  Thus, it appears that both viruses replicated 
following the divergence of the human and chimpanzee lineage six million years ago, 
with cross species transmissions resulting in endogenizations within diverse old world 
primate species, but not in the ancestors of modern humans.  It remains possible that a 
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genetically encoded protection guarded human ancestors from CERV1 and CERV2 
invasion during the time that they were becoming endogenized in the non-human primate 
lineages 1.3 to 6.0 million years ago (8).  An exploration of such possibilities, though, 
warrants an initial discussion of the ways in which retroviral replication depends on some 
host factors and is assaulted by others. 
  
Retroviral envelopes and cell-surface receptors 
 Infection of a cell with a retrovirus particle begins with the interaction of the viral 
envelope glycoprotein with a cell surface receptor (Figure 2).  The maturation of the 
envelope involves furin cleavage during its transport through the Golgi to form a surface 
protein (SU) and a single-pass transmembrane protein (TM) (21, 22).  SU contains 
receptor-binding regions, while TM is responsible for fusion of viral and cellular 
membranes.  In HIV, trimeric gp120 binds to receptor molecules and sits atop trimeric 
gp41 (23), both of which are known to be the target of antibodies that are capable of 
neutralizing the virus [reviewed in (24, 25)].  Although monoclonal antibodies have been 
isolated whose recognition of antigens on the envelope surface is dependant on 
glycosylated residues (26, 27), glycans are likely to generally increase the difficulty in 
acquiring antibody recognition of key envelope structures (28).  Indeed, mutagenesis at 
glycosylated residues generally increases the neutralization sensitivity of HIV-1 envelope 
to polyclonal sera (29-31).  In addition, evolution by the virus repeatedly allows it to 
persist in the face of continual antibody generation by the host (32-34).  gp120 contains 
five variable loops and sequence flexibility in these regions, along with alterations in 
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Figure 2.  The retrovirus replication cycle.  The left panel depicts steps that take place during 
retroviral infection and the right panel describes the production of virus particles.  The various 
stages of the cycle are referred to throughout this chapter.  Taken from Goff Nature Reviews 
Microbiology 2007 (35). 
 
gp120 glycosylation, aid the virus in its escape from immune responses (23, 34, 36-39). 
 HIV-1 cell tropism is greatly limited by the use of CD4 as its receptor, which is 
primarily expressed only on helper T-cells, macrophages, and dendritic cells (40).  Target 
cell range is further narrowed by the requirement for gp120 to also bind to either CCR5 
or CXCR4 chemokine receptors (41-44).  The identification of two HIV-1 co-receptor 
usages largely explained the ability of only some isolates to induce cell fusions (or 
syncytia) in laboratory T cell lines, in that the ability to induce T cell syncytia was 
associated with CXCR4 usage (45-47).  Intriguingly, most transmitted viruses use CCR5 
(R5-tropic) and about 50% eventually undergo a shift to CXCR4 usage (X4-tropic) that is 
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temporally correlated with disease progression (48, 49).  Determinants of this differential 
co-receptor usage are largely found in the V3 loop of gp120 (50-55).  It appears that the 
co-receptor utilized by HIV-1 can dictate which CD4
+ 
T cell compartment it 
predominantly infects.  Studies in rhesus macaques using a chimeric SIVmac containing 
either X4-tropic or R5-tropic HIV-1 envelopes (X4 or R5 SHIVs) have demonstrated that 
X4-tropism causes the preferential depletion of naïve CD4+ T cells in the peripheral 
blood and in solid lymph tissue, while R5 SHIVs primarily deplete memory T-cells in the 
gut (56-58).  Further analyses confirmed that biased patterns of infection correlated well 
with the depletion of specific cellular compartments.   
 It remains unclear, though, whether a shift in target cell range during the 
emergence of X4-tropism from initial R5-tropism causes disease progression or if, quite 
the opposite, the depletion of target cell availability during disease progression forces 
tropism change.  In either case, there likely exists a selective pressure that prevents or 
delays the emergence of X4-tropic variants.  Indeed, change from an R5- to an X4-
tropism during SHIV infection in rhesus macaques have a propensity to occur in animals 
with relatively weak immune responses and the resulting X4-tropic viruses typically 
display an increased susceptibility to neutralization by both polyclonal and monoclonal 
antibodies (59-62).  These observations support the notion that immune system 
abnormalities are just as likely to be a cause rather than an effect of X4-tropic virus 
emergence.    
 In addition to defining a viral pathogen’s specificity for certain cell types within 
an infected host, receptor usage is also crucial to the ability of a virus to transmit between 
species.  Indeed, cellular receptors are often a primary determinant of gammaretroviral 
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host range.  In the case of MLV, five groups of viruses exist that each display a particular 
receptor usage and host range (termed interference groups) (63).  It is thought that two 
variable regions in MLV SU that surround a conserved core of !-sheets are responsible 
for determining receptor specificity (64-66).  Ecotropic MLVs use the mouse cationic 
transport protein (CAT-1) for entry and display a strictly murine host range (67). In 
contrast, an amphotropic envelope can allow MLV to replicate in cells from a variety of 
mammalian species through a shift in their receptor usage to the inorganic phosphate 
transporter, PIT-2 (68-70).  A variant of amphotropic MLV, 10A1, is able to use both 
PIT-2 and the closely related PIT-1, placing it in an interference group that includes 
gibbon ape leukemia virus (GALV) and feline leukemia virus (FeLV) group B (71).   
 Similar to the host range expansion allowed by amphotropic envelope, MLV 
recombinants carrying envelopes from xenotropic or polytropic endogenous MLVs are 
able to use the xenotropic/polytropic receptor (XPR-1), allowing for distinct host ranges 
that are determined by their differing interactions with the same receptor (72-77).  
Chimeras of human and hamster XPR1 demonstrated that the third extracellular loop 
from human XPR1 allows binding of both xenotropic and polytropic MLV, while the 
inclusion the second human extracellular loop results in a receptor that is specific for 
xenotropic MLV (78).  Although polytropic MLV generally has a broader rodent tropism 
compared to its xenotropic relative, some wild mice do express XPR1 proteins capable of 
allowing xenotropic MLV infection (79, 80).  It is tempting to speculate that the observed 
mouse XPR1 variability is the product of selective pressure imposed by MLV. 
 The determination of species-specific tropism by envelope and receptor 
interaction is also a common theme among gammaretroviruses other than MLV.  For 
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example, it has been posited that mutations in the GALV envelope allowed for an 
expansion of zoonotic potential that led to koala retrovirus, an endogenous retrovirus that 
continues to replicate exogenously in wild koalas (81, 82).  In the case of FeLV and 
PERV, both are divided into three groups, each with a distinct receptor usage that 
determines particular species tropisms.  Interestingly, all FeLV and PERV receptors that 
have been identified are transport proteins.  FeLV group A is transmitted between felines 
using the cell surface receptor, thiamine transporter 1 (THTR-1) (83).  Within the new 
host, FeLV-B and/or FeLV-C pathogenic variants emerge that, unlike their FeLV-A 
predecessor are able to infect canine and human cells.  FeLV-B arises through 
recombination with endogenous retroviruses and consequently has a receptor usage that 
is shifted to feline PIT-1 or PIT-2 and is also capable of using human PIT-1 (84-86).  
FeLV-C emerges through a multi-tropic intermediate with point mutations that allow for 
infection via a heme export protein, FLVCR1 (87-90).  This recurrent shift toward 
FLVCR1 usage is associated with red cell aplasia, perhaps a consequence of heme 
transport disruption during erythroid progenitor cell development.  Porcine endogenous 
retroviruses are also divided into three groups with variable receptor usage, two of which 
are able to infect human cells and have thus been a major concern to the 
xenotransplantation field (91).  PERV-A is able to infect human cells through the use of 
the gammahydroxybutyrate transport protein, PAR-1, or the riboflavin transport protein, 
PAR-2 (92).  The PERV-B receptor is currently unknown.   
 Also in line with the recurring theme of transport proteins as gammaretrovirus 
receptors is the use of the sodium-dependent neutral amino acid transporter (ASCT2) by 
the baboon endogenous retrovirus (BaEV)/RD114 feline endogenous retrovirus/simian 
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retrovirus type D (SRV, including mason-pfizer monkey virus) interference group (93-
95).  BaEV, in addition to human ASCT2 and unlike the other members of its 
interference group, is also able to use ASCT1 from humans and mice (96).  After the 
removal of protective N-linked glycosylations, mouse and hamster ASCT1 become 
functional receptors for the entire interference group (97).  It should be noted that the 
usage of ASCT2 by SRV was likely made possible by an ancient recombination event 
between two quite distinct viruses.  This hypothesis was prompted by the observation that 
reverse transcriptase phylogeny clearly classifies SRV as a betaretrovirus, while analyses 
using envelope sequences reveals close relatedness with gammaretroviruses in its 
interference group (i.e. BaEV and RD114) (98, 99).  This emphasizes that virus 
classification that lacks inspection of receptor-binding regions can be misleading when 
used to predict receptor usage.   
 Sequence divergence in receptor binding regions does not necessarily predict that 
two viruses use distinct receptors.  The HERV-W envelope SU is very distinct from that 
of RD114, BaEV, and SRV.  Nevertheless, the ability of cells expressing ASCT2 to 
readily fuse with cells expressing the HERV-W envelope, syncytin, suggests that HERV-
W also used ASCT2 as a cellular receptor during its exogenous replication (95, 100).  
The observation that syncytin is highly expressed in the placenta led to the hypothesis 
that its fusogenicity is responsible for syncytiotrophoblast formation during placental 
development.  An in vitro model of cytotrophoblast maturation demonstrated that 
syncytin and ASCT2 expression co-linearly increase during differentiation and inhibition 
of syncytin expression leads to a decrease in cell fusions (101).  Also in support of a 
cellular function for syncytin is the conservation of the following features among diverse 
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ape species and 24 human individuals: LTR promoter activity, splice sites required for an 
envelope mRNA, the envelope translational start site, and fusogenic activity (102).       
 
Post-entry events and restriction factor encounters 
 TM-mediated fusion of the viral and cellular membranes allows the core of the 
virus to enter the cytoplasm of the target cell.  Following entry, the capsid shell 
disassembles and the RNA genome is reverse transcribed to form a double-stranded 
DNA.  During this time, the virus is susceptible to assault by host factors that are capable 
of capsid recognition, and others that act on the viral DNA during reverse transcription.  
Fv1 is a mouse gene that is similar to the mouse endogenous retrovirus-L Gag and is able 
to cofer strain-specific protection of mice from MLV infection (103-105).  MLV variants 
displaying an N- and B-tropism, determined by differences in their capsid N-terminal 
domain, are resistant to the N and B alleles of Fv1, respectively (106, 107).  Although the 
exact mechanism of restriction by Fv1 is elusive, it is clear that its capsid-specific action 
depends on Fv1 molecules in the target cell that are saturable at high multiplicities of 
infection.  N-MLV is also sensitive to post-entry restriction by some tripartite motif 
(TRIM) 5" proteins (108-110). 
 TRIM5" is a primate restriction factor that was first recognized for its ability to 
form a major block to HIV-1 infection in rhesus macaques (108, 111, 112).  Although 
human TRIM5" is unable to restrict HIV-1, it is active against N-tropic MLV (108-110).  
The species-specific sensitivities of viruses to TRIM5", like Fv1 vulnerability, are 
determined by amino acid residues found in the capsid N-terminal domain that are 
exposed on the surface of the viral core prior to disassembly (113-115).  TRIM proteins 
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share homologous RING finger, B-box, and coiled coil domains (116).  In addition to this 
tripartite motif, TRIM5" also contains a SPRY/B30.2 domain.  It has been demonstrated 
that the SPRY/B30.2 domain of TRIM5" is responsible for capsid recognition, while the 
RING and B-box domains contribute an unknown, but crucial function during restriction 
(117-121).  Additionally, a coiled-coil domain allows TRIM5" multimerization and can 
allow non-functional truncated TRIM" mutants to have a dominant negative effect (121). 
The TRIM5" RING finger has been shown to have E3 ubiquitin ligase activity and 
induces auto-polyubiquitination, which can affect the half-life of the protein (122, 123).  
During restriction, TRIM5" has been observed to undergo proteosome-dependent 
degradation (124).  The involvement of the proteosome in restriction is unclear, though, 
given that treatment of cells with proteosome inhibitors can cause an increase in the 
formation of reverse transcription products but are unable to cause an increase in 
infection during TRIM5"-mediated restriction (125-128). 
 A cellular prolyl isomerase is also able to modulate HIV-1 infection.  It has been 
shown that cyclophilin A (CypA) interacts with HIV-1 Gag and is efficiently incorporates 
into virions (129-131).  Disruption of CypA packaging with a small molecule 
(cyclosporine A) or mutation at a single proline residue in Gag decreased infection in 
human cell lines.  In later work, though, expression of CypA in target rather than 
producer cells was shown to modulate HIV-1 infection and these effects differed 
according to both the capsid sequence and target cell line used (132, 133).  For example, 
cyclosporin A treatment of Jurkat and HOS cells decreased infection.  In contrast, 
treatment of HeLa and H9 cells did not affect infection with wildtype virus and actually 
enhanced infection with virus containing the A92E or G94D capsid cyclophilin A 
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resistance mutations (134, 135).  Cyclophilin A in the target cell, therefore, has 
differential effects on infection depending on amino acid identities on the incoming 
capsid.  Furthermore, the cell type specificity of these phenomena suggest a possible 
involvement of unknown host factors. 
 A specific linkage between cyclophilin A and restriction factors was demonstrated 
by the observation that disruption of its interaction with capsid using cyclosporine A or 
siRNA knockdown of target cell cyclosporine A was able to relieve the restriction of 
HIV-1 by rhesus macaque TRIM5" (136-138).  Thus, it appears that the cyclophilin A-
capsid interaction can be crucial to TRIM5" activity.  In support of this assertion is the 
observation that convergent evolution has produced TRIM-cyclophilin A (TRIMCyp) 
fusion proteins in new world and old world monkeys by gene retrotransposition (139-
144).  Recurrent TRIMCyp formation emphasizes the antiviral potential that linkages 
between cyclophilin A and TRIM5 activities can offer and, furthermore, suggests that 
their combined function has provided primates with crucial protections from retroviruses 
throughout history.  Additionally, high ratios of nonsynonymous to synonymous mutation 
have been observed in primate TRIM5" genes, suggesting that the evolution of these loci 
has been driven by positive selection (145, 146).  The conclusion that TRIM5" genes 
have been under positive selection during primate evolution further suggests that they 
were rescuing primates from viral challenge long before the modern infections that we 
observe today. 
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Figure 3.  Reverse Transcription.  RNA is represented by red lines and DNA, by thick black lines.  
Each step is described in the text. Drawing is by A. Telsnitsky and is taken from Field’s Virology, 
Fifth Edition (147).  
 
 If the retroviral replication cycle is able to proceed normally, reverse transcriptase 
next synthesizes the viral cDNA to be integrated into the cellular genome (Figure 3) 
(148-150).  DNA synthesis does not commence until after entry into the target cell, 
perhaps due to the lack of deoxyribonucleotides in the virion.  Virion-packaged cellular 
tRNA is usurped for the initiation of reverse transcription at the primer-binding site 
(PBS), located just 3’ of the 5’ long terminal repeat (LTR).  The 5’ LTR is reverse 
transcribed first, forming the minus-strand strong-stop DNA before degradation of the 
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first template region by the RNase H domain of reverse transcriptase.  The freed strong-
stop DNA next binds to the opposite end of the viral RNA through complementation with 
sequence in its 3’ end, thus allowing reverse transcription and the coupled RNase H 
activity to proceed through all open reading frames to the 5’ end of the PBS.  RNase H 
activity initially spares a polypurine tract (PPT) adjacent to the 3’ LTR and this 
remaining RNA serves as a primer for synthesis of the 3’LTR positive strand before 
further RNA digestion.  A new PBS is synthesized by the reverse transcription of the 5’ 
end of the tRNA (plus-strand strong-stop DNA) prior to tRNA digestion, again by viral 
RNase H.  Finally, the DNA-templated completion of both strands is prompted by 
circularization via base pairing at the PBS. 
 The existence of single-stranded DNA intermediates during reverse transcription 
leaves the virus vulnerable to attack by already present cytidine deaminases, carried from 
the virus-producing cell by the virion itself.  The apolipoprotein B mRNA editing enzyme 
catalytic polypeptide (APOBEC) protein family of cytidine deaminases includes at least 
two restriction factors that are capable of acting potently on retroviruses- APOBEC3G 
and APOBEC3F (151-155).  APOBEC3B, APOBEC3C, APOBEC3DE, and 
APOBEC3H have also been shown to have smaller degrees of antiviral activity (156-
161).  When APOBEC3 is expressed in virus-producing cells, they are incorporated into 
budding viral particles through their interaction with the nucleocapsid domain in an 
RNA-dependent manner (162-168).  Following reverse transcription in the target cell, 
APOBEC3 proteins are able to deaminate deoxycytidine residues on the nascent negative 
sense cDNA to deoxyuridine (169-171).  During synthesis of the DNA positive strand, 
the presence of aberrant deoxyuridine results in guanosine to adenosine mutation.   
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 APOBEC3-induced cytidine deamination takes place with biases toward specific 
dinucleotide contexts.  APOBEC3G prefers cytidines immediately 3’ of another cytidine, 
which results in GG to AG mutations; while the other APOBEC3 proteins deaminate 
cytidine in a TC dinucleotide context and these events cause GA to AA mutations 
(APOBEC3G can also cause GA to AA mutations but far less often than GG to AG 
mutations) (153-155, 160, 161, 170, 171).  The frequency of hypermutation can vary 
across the viral genome according to the length of time that single-stranded DNA is 
exposed prior to complementation to nascent positive-strand DNA (171).  In HIV-1, this 
variability manifests as two gradients with increasing G to A mutation frequency in the 5’ 
to 3’ direction that peak just 5’ of the polypurine tracts (172).  
 Human APOBEC3G was first identified as a restriction factor when it was found 
to determine the permissivity of cell lines to HIV-1 virions that lack the Vif protein 
(HIV-1 deltaVif) (152).  Vif is able to inhibit APOBEC3G by recruiting it to a cullin-
5/E2 ubiquitin ligase complex.  This results in the polyubiquitination and subsequent 
proteosomal degradation of APOBEC3G before it can be incorporated into the budding 
virion (173, 174).  The ability of Vif to inhibit APOBEC3 proteins varies in a species-
specific manner (156).  HIV-1 Vif is not able to induce the degradation of rhesus 
macaque APOBEC3G or APOBEC3F and this, in part, explains the inability of HIV to 
infect these animals (155, 175).  The APOBEC3 gene family has expanded from one 
gene in mice to seven genes in primates and the primate genes, including APOBEC3F 
and APOBEC3G, have been under strong positive selection since before the divergence 
of old and new world monkeys 33 million years ago (176, 177).  Therefore, it appears 
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that, like TRIM5 proteins, APOBEC3 provided a critical defense in primates against 
retroviruses long before the activities we observe today against modern viruses.   
 The restriction of Vif-deficient HIV-1 by APOBEC3F/G could take place through 
several possible mechanisms.  First, the amount of proviral DNA is decreased during 
restriction (178, 179).  This could be the result of the removal of uracil from 
deoxyuridine by uracil DNA glycosylase (UNG), followed by the action of cellular 
DNases.  Indeed, UNG-2 is incorporated into virions but a depletion of UNG-2 in virus-
producing cells is not able to rescue HIV-1 from restriction, leaving this mechanism 
unsupported (180).  It has also been proposed that APOBEC3F- and APOBEC3G-
mediated restriction may be independent of deaminase activity (181-184).  APOBEC3F 
and APOBEC3G mutants containing changes to their C-terminal zinc coordinating 
catalytic site were not competent as deaminases but still retained at least 60% of their 
antiviral activity.  Contrary to this, it had already been shown that mutating these same 
sites does destroy the antiviral activity of APOBEC3G (169).  Furthermore, it has been 
argued that any deaminase-independent restriction observed is only made possible by in 
vitro over-expression of APOBEC3G, as evidenced by a complete lack of restriction 
capability in deaminase-deficient mutants when their expression levels are comparable to 
APOBEC3G expression in activated peripheral blood mononuclear cells (PBMC) (185-
187).  Although the in vivo applicability of a deaminase-independent restriction of HIV-1 
by APOBEC3G remains controversial, a variety of mechanisms have been proposed 
including inhibition of tRNA priming, strand transfer, both early and late viral DNA 
production, and integration (188-191). 
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Perhaps the most intuitive explanation for the antiviral effects of A3 proteins, 
though, is a debilitation of viral progeny by G to A hypermutation in the provirus.  This is 
especially likely in the case of APOBEC3G mediated restriction, which due to the bias in 
the dinucleotide context of APOBEC3G-triggered deamination, has a propensity to cause 
tryptophan codons (UGG) to mutate to stop codons (UAG).  When both mutated 
dinucleotide contexts are considered, the high degree of hypermutation found in 
individual proviruses would likely impact their fitness through frequent nonsynonomous 
mutations. 
 
Hypermutation in vivo 
Investigations into the effects of hypermutation on HIV-1 are directly applicable 
to HIV evolution within an infected individual because, in spite of Vif activity, 
hypermutation does occur in vivo.  Janini et al. analyzed protease genes integrated in 
peripheral blood mononuclear cells (PBMC) from patients at different disease stages and 
infected with a variety of HIV subtypes (192).  Abundant hypermutated protease 
sequences were detected in 43% of the 53 patients studied.  In the hypermutated 
sequences, 20 to 94% of G residues in the GG and GA dinucleotide contexts were 
mutated to A, which is consistent with APOBEC3G and APOBEC3F activity, 
respectively.  Mutations in the GA context were twice as frequent as mutations in the GG 
context suggesting that APOBEC3 proteins other than APOBEC3G may predominate in 
HIV-1 hypermutation in vivo.  Consistent with this hypothesis is the observation that 
HIV-1 Vif is less efficient at triggering APOBEC3F degradation compared to 
APOBEC3G degradation (155).   
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 In another study, Kieffer et al. searched for hypermutated RT and protease 
sequences in both plasma virus and resting CD4
+
T cells (193).  Plasma virus and PBMC 
were isolated from nine patients and the PBMC was fractionated to isolate resting CD4
+
T 
cells.  The patients had a undetectable viremia due to suppression by highly active 
antiretroviral therapy (HAART).  Resting CD4
+
T cells were studied because even when 
viremia is kept at low levels by HAART, integrated latent viral proviruses remain 
abundant in these cells.   There were no hypermutated sequences detected in plasma 
virus; but in the case of resting CD4
+
T cells, at least one hypermutated sequence was 
found in each patient.  The hypermutation was manifested as G to A changes with 98% of 
these changes occurring in the GA or GG dinucleotide context.  Unlike the study 
conducted by Janini et al., mutations within the GG context were four times more 
common than mutations within the GA context.  Perhaps the use of resting CD4
+
T cells, 
as opposed to unfractionated PBMC, from patients on successful HAART narrows the 
study to a latent pool containing inactive hypermutated proviruses that have primarily 
been mutated by APOBEC3G.  In support of this assertion is the observation that 
APOBEC3G is more active against HIV delta Vif than APOBEC3F and has a greater 
propensity to induce stop codons (155).  Additionally, APOBEC3G has been observed in 
cell culture experiments to be capable of causing a small amount of GG to AG mutations 
in HIV sequences, even in the presence of Vif (194). 
 Overall, it is unclear which APOBEC3 protein(s) are predominately active against 
HIV in vivo.  The preferred dinucleotide context of G to A mutations may vary greatly 
within a single patient.  It is likely that the ability of each deaminase to hypermutate HIV 
depends on the potency of the Vif species encountered.  It has been shown that a variety 
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of single amino acid changes in Vif can affect its specificity for APOBEC3F, 
APOBEC3G or both (195, 196). A study by Simon et al. described highly variable Vif 
sequences within individual patients and inactive Vif genes were isolated from all seven 
patients studied (197).  Furthermore, Vif genes were isolated that were active against 
APOBEC3F and APOBEC3G, APOBEC3F but not APOBEC3G, or vice versa.  
Concordantly, the predominance of either GG to AG or GA to AA substitutions varied 
between hypermutated proviruses.  This suggests that Vif variability can allow for a large 
range in both the quantity and the dinucleotide context of hypermutation in vivo.  
Aside from the generation of stop codons by APOBEC3G activity, any increase in 
the amount of random mutation could be very deleterious to the overall fitness of an 
HIV-1 population.  It has been argued that HIV-1 reverse transcriptase has evolved a 
fidelity high enough to maintain sufficient sequence integrity, but low enough to allow 
rapid sequence diversification (198).  An increase in the frequency of random mutations 
may push the mutation rate high enough to allow the accumulation of a significant 
number of deleterious mutations, thus giving rise to a genetic load with significant 
impacts on the overall population fitness.   
On the other hand, the ability of HIV reverse transcriptase to generate 
recombinant genomes could allow for the continual regeneration of fit viruses despite the 
generation of hypermutants.  Recombination in retroviruses is possible because it is an 
inherent trait of retroviral virions to contain two viral genomes (199-201).  When virus is 
produced from a cell containing multiple infections, packaging of homologous RNA from 
more than one proviral source can occur.  This results in the presence of differing 
templates for reverse transcription during the subsequent infection.  It appears that 
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reverse transcriptase is capable of jumping between templates multiple times during a 
single cycle of replication (202, 203).  The resulting viral DNA that continues on to 
integration is, thus, a recombinant of the two genomes used during reverse transcription.  
It has long been theorized that recombination has repeatedly arisen throughout biology, in 
part, to ameliorate the effects that a load of deleterious mutations can have on a 
population (204-207).  It is possible that it is the high frequency of recombination in 
HIV-1 that allows it to cope with high mutation rates and, perhaps, even make use of the 
variability that hypermutation offers.  Recombination between hypermutants and 
genomes untouched by deamination may generate fit viruses containing a relatively low-
level of APOBEC3-induced mutation. 
Mutations that resemble those imposed by APOBEC3 proteins (i.e. G to A within 
GG or GA contexts) have been observed in viruses that have a low burden of mutation 
compared to proviruses that have been crippled by hypermutation (208-210).  Low levels 
of putative APOBEC3-induced mutation were shown to include residues within 
confirmed cytotoxic T lymphocyte epitopes that evolved rapidly during early infection 
(210).  This suggests that variability generated by APOBEC3 activity can be utilized by 
HIV-1 during immune evasion.  Furthermore, the occurrence of drug resistance mutations 
within sequence contexts targeted by APOBEC3 suggests that hypermutation also has the 
potential to contribute to drug resistance evolution (reviewed in Chapter IV).  APOBEC3 
activity in vitro has been shown to induce the emergence of 3TC escape mutants, though 
this required the cloning of hypermutated loci from unfit variants into wildtype virus 
(211).  It is possible that this recapitulated recombination events that can occur between 
replication competent virus and inactivated hypermutants in vivo.  So, the question arises 
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for a viral population within an infected host: is hypermutation induced by APOBEC3 a 
burden or a benefit? 
 
Post-reverse transcription events and production of viral progeny  
Following reverse transcription, the newly synthesized viral DNA transports to 
the nucleus as part of a pre-integration complex that includes integrase, reverse 
transcriptase, and Gag components (212, 213).  The biochemical steps of integration have 
been extensively studied in vitro [reviewed in (214) and Figure 4].  First, integrase 
transforms the blunt ends of the provirus into 5’ overhangs by the removal of two 
nucleotides, typically TT, leaving recessed strands ending in CA.  Second, the newly 
formed 3’ hydroxyls each undergo a nucleophilic attack of phosphorous in the cellular 
DNA.  The resulting transesterification generates single-stranded nicks between the 5’ 
end of each proviral DNA strand and the displaced 3’ ends of the cellular DNA.  Two 
nucleotides at the free 5’ ends of viral DNA and several cellular nucleotides on the 
opposite, ligated strand lack base pairing.  These structures are promptly repaired, likely 
by cellular machinery, with the insertion of nucleotides that are complementary to 
unpaired cellular sequence followed by a final transesterification that replaces the two 
unpaired viral nucleotides and removes the nick.   
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Figure 4.  Retroviral integration.  The steps involved in the formation of provirus are shown.  
These include processing of the viral DNA ends by integrase, nucleophilic attack of cellular DNA 
phosphorous atoms by 3’ hydroxyls on the viral DNA (or ‘strand transfer,’ also catalyzed by 
integrase), and finally repair single-stranded nicks.  Adapted from Goff, Ann. Rev. Gen. 1992 
(214). 
 
With the aid of cellular factors, the integrated provirus is now available for both 
gene expression and inheritance by cellular progeny.  The integrated viral LTR contains 
promoter elements that prompt transcription by the cellular RNA polymerase (215-217).  
In the case of HIV-1, the viral Tat protein stimulates transcription through the association 
of a cyclin T/CDK9 complex with the viral TAR RNA nascent transcript (218-228).  This 
results in hyperphosphorylation of the RNA polymerase II C-terminal domain and, 
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consequently, transcript elongation (225-228).  Full-length viral transcripts are capped, 
poly-adenylated, and exported for either virion packaging or translation of Gag and 
GagPol.  Other transcripts are spliced for envelope translation and during the production 
of complex retroviruses, alternative splicing allows for the expression of several 
accessory genes (229).  In HIV-1, the export of intron-containing transcripts requires the 
binding of the virus-encoded Rev protein to Rev-responsive elements in the RNA (230-
236).   
Translation of unspliced mRNA produces both Gag and GagPol proteins.  The 
inclusion of Pol on 5-10% of Gag proteins occurs when structured RNA components in 
the transcript cause the ribosome to “ignore” the Gag stop codon.  In some retroviruses 
(e.g. gammaretroviruses) a tRNA is utilized at the stop codon, while in other viruses (e.g. 
lentiviruses) slippage of the ribosome causes a frame shift (237-239).  The Gag and 
GagPol proteins accumulate on viral RNA at the plasma membrane to form nascent 
virions (240-242).  Fission of viral and plasma membrane allows assembled particles to 
bud from the cell surface.  The membrane manipulations required for such an event are 
catalyzed by cellular class E vacuolar sorting machinery, which are proteins that 
normally execute the topologically similar formation of multi-vesicular bodies [reviewed 
in (243, 244)].  Recruitment of class E machinery requires Gag amino acid motifs, termed 
late-budding domains (PT/SAP, LYPxL, or PPxY).  Finally, processing of Gag and 
GagPol by the viral protease facilitates maturation of the budded particle (245, 246).  Gag 
and GagPol cleavages produce mature matrix, capsid, nucleocapsid, protease, reverse 
transcriptase, and integrase proteins. 
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Following the budding of a new virion, and before escape from the surface of the 
very cell that produced it, the virus may be assaulted by the cell through the action of the 
tetherin protein.  Tetherin was identified as a host restriction factor based on both its 
interferon induction and specific expression in cells that were non-permissive to 
replication of HIV-1 lacking expression of the Vpu accessory protein (247, 248). 
Biochemical characterization and the replacement of tetherin components with analogous 
protein structures have demonstrated that tetherin accomplishes restriction through a 
direct bridging of virions to cells, with one end of tetherin attached to the viral membrane 
and the other to the plasma membrane (249).  Importantly, in the absence of specific 
antagonism, tetherin seems to act broadly against enveloped viruses without any 
identified protein specificity (250). 
 
Endogenous retroviruses and the lessons that they can offer 
We refer to the cycle of extracellular virion production and subsequent cellular 
infection as exogenous virus replication.  There is utility in such a designation because 
the mere presence of provirus in cellular genomes also allows for its replication by the 
cell’s indiscriminate DNA polymerase.  Such endogenous replication dictates that any 
descendent of an infected cell will contain a copy of the integrated provirus.  Robin 
Weiss first pointed out that heritable elements in cells from chickens were capable of 
allowing the replication of Rous sarcoma viruses (RSV) that were normally incompetent 
without the aid of a helper virus (5).  Later Weiss and Peter Vogt were able to use 
carcinogens to induce the release of avian tumor viruses from uninfected chicken cells 
(251).  These pivotal observations, in combination with the observed heritability of some 
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avian leukosis virus (ALV) antigens (252), led to the theory that retroviruses are capable 
of invading the host germ line and can consequently become endogenized into the 
organism-wide genome of progeny.   
Sequencing of primate genomes has expanded our appreciation for retrovirus 
endogenizations that have taken place during our own evolution.  At least 8% of human 
genomic sequence is the result of retroviral infections (253).  Genomic sequence, 
therefore, provides an ancient historical account of past retroviral epidemics.  
Experiments with human endogenous retrovirus K (HERV-K), a virus that was 
repeatedly endogenized in the ancestors of modern primates for millions of years, 
demonstrated that our understanding of ancient viruses does not have to end with their 
sequencing (13, 254).  A consensus of inactive human-specific HERV-K integrations was 
constructed and gave rise to infectious virus particles in vitro.  The virus, perhaps not 
produced for over one million years, was further characterized as being resistant to 
TRIM5 and APOBEC3G restriction factors, but sensitive to human APOBEC3F.  It may, 
therefore, be the case that members of the HERV-K family contributed to the positive 
selection imposed on the APOBEC3F locus over the course of its evolution.  These initial 
endeavors in “paleovirology” began to demonstrate the potential that such studies have in 
describing the long-term co-evolution of hosts and retroviruses. 
The work described herein, sought to extend the exploration of ancient viral 
challenges to include primate gammaretroviruses.  A comparison of the chimpanzee 
genome with our own revealed that there were distinct differences in our retroviral 
encounters since the divergence from a common ancestor six million years ago (8, 9).  In 
fact, 7% of chimpanzee-human INDEL variation is attributable to retrovirus integrations.  
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A close relative of the modern MLV, CERV2, and a more distant relative, CERV1, are 
present in the genomes of chimpanzees (Figure 5) and other non-human primates, but are 
entirely absent from the human genome (8, 9, 20).  Therefore, CERV1 and CERV2 may 
reveal genetic factors that have influenced cross-species transmissions over the course of 
chimpanzee and human speciation.  Furthermore, such investigations could support a 
notion that a broad repertoire of retroviruses has imposed selective pressures that have 
shaped the evolution of modern host factors. 
First, we asked whether host factors that restrict modern retroviruses were able to 
target CERV1 and CERV2 during their exogenous replication (255).  Due to the close 
relatedness of CERV1 and CERV2 with moloney MLV, we were able to construct 
functional recombinants containing CERV1 or CERV2 capsid N-terminal domains within 
an MLV GagPol context.   The resulting chimeric virions were shown to be largely 
resistant to restriction by human, chimpanzee, and rhesus macaque TRIM5".  Therefore, 
we cannot speculate that TRIM5" was involved in a protection of human ancestors from 
CERV1 or CERV2 infection.  An inspection of CERV1 and CERV2 sequences, though, 
revealed scars likely made by APOBEC3G.  Namely, G-to-A mutations were observed 
with bias toward GG dinucleotides.  Homologues in the rhesus macaque carried G to A 
mutations with both GG and GA dinucleotide contexts implying encounters with multiple 
APOBEC3 proteins.  Further work in vitro demonstrated that APOBEC3G is capable of 
restricting infection by virions carrying CERV2 structural proteins.  APOBEC3 proteins 
were therefore likely to be capable of restricting these viruses and, in return, infections by 
them may have contributed to the positive selection imposed on APOBEC3.  
Furthermore, debilitating APOBEC3-induced mutation is likely responsible for the  
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Figure 5.  Phylogeny of chimpanzee endogenous retroviruses (CERVs).  The unrooted neighbor 
joining tree is based on CERV reverse transcriptase sequences and those from several 
representative retroviruses as indicated.  Three classes of endogenous retroviruses are designated: 
class I is related to modern gammaretroviruses, class II is related to modern betaretroviruses 
(class II CERVs are homologous to HERV-K), and class III is distantly related to modern 
spumaviruses.  An enlarged portion is shown to indicate the position of CERV1, CERV2, and 
MLV on the tree.  Adapted from Polavarapu et al. Genome Biology 2006 (8). 
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inactivity of many of the individual proviruses.  This work allows us to speculate about a 
role of APOBEC3 proteins in limiting exogenous replication of these viruses. 
 The potential impacts that APOBEC3-induced mutation can have on an evolving 
population were studied using HIV-1 in vitro.  Virus was allowed to replicate in the 
presence of varying degrees of APOBEC3 activity.  It was evaluated whether the 
resulting hypermutation was capable of accelerating drug resistance evolution or if it 
constitutes a genetic load that hinders the emergence of escape mutants.  Populations of 
HIV-1 delta-Vif that carried significant genetic loads were not observed to acquire drug 
resistance, even when challenged in fully permissive cells.  A low level of APOBEC3-
associated mutation was also observed in Vif-positive virus and this modest degree of 
diversity did not impede and may have contributed to its evolution. 
 To extend our understanding of host factors that did not assault, but rather aided 
CERV2 during the time that it replicated, we constructed a functional consensus envelope 
gene.  MLV particles carrying this envelope displayed a broad species tropism in tissue 
culture and were further used in a genetic screen that identified copper transport protein 1 
(CTR-1) as a novel cell-surface receptor that was used by CERV2 during ancient times.  
The only species tested that was non-permissive to CERV2 was the hamster and its lack 
of permissivity can be explained by subtle differences in CTR1.  The identity of the 
CERV2 receptor does not predict a limited primate host range.  This work does 
demonstrate, though, that reconstructions of ancient envelope genes can allow the 
discovery of host proteins that have been used as viral receptors throughout evolutionary 
history.    
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Chapter II.  Materials and Methods 
 
 
Virions and cell lines 
 Production of virions was accomplished by polyethyleneimine (PEI) 
cotransfection of 293T cells.  A three-plasmid system was used to generate virus particles 
that were only capable of a single cycle of replication.  Two scales are described for 
production in either 24-well or 100mm dishes.  The transfections included plasmids 
expressing moloney murine leukemia virus GagPol or HIV-1 GagPol from the NL4.3 
laboratory-adapted strain (500ng or 6!g); a vector containing an MLV or HIV-1 
packaging sequence proceeding a reporter gene and/or a selectable marker (500ng or 
6!g); and an envelope glycoprotein from either vesicular stomatitis virus (VSV) for its 
high infectious titer in a broad range of target cells (100ng or 1!g), or a retroviral 
envelope as indicated in the text (500ng or 6 !g).  The reporter vectors used were CNCG 
(256) and CSGW (257), which are MLV and HIV vectors, respectively, that both contain 
an eGFP expression cassette. 
 Plasmids were mixed in serum-free DMEM (50µL or 1mL) followed by addition 
of 4µg PEI per 1µg of total DNA (from a 1µg/µL PEI stock solution).  This mixture was 
vortexed briefly and incubated at room temperature for 10 minutes before addition to 
293T cells, which were 60-80% confluent in freshly added media (500!L or 5mL). 
Transfections were allowed to proceed overnight before a change to fresh media (500!L 
or 8mL).  Supernatants were collected 48 hours post-transfection and purified through 
0.22!m filters.  All infections were allowed to proceed overnight and 5!g/mL polybrene 
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was included on all cells except CHO-PGSA.  A detailed description of MLV particles 
containing endogenous capsid N-terminal domains can be found in a separate section 
below.     
 The LMN8iresZeo cDNA plasmid library was a gift from Stuart Neil and was 
generated as follows.  Total RNA was extracted using Invitrogen TRIzol from 5x10
6
 
HeLa, purified with two sequential chloroform extractions, precipitated in isopropanol, 
and washed in 70% ethanol.  mRNA was purified from total RNA using Qiagen Oligotex 
polyA+ resin.  cDNA containing SfiI sites was synthesized and amplified using Clontech 
SMART primers and Invitrogen size exclusion columns were used to dispose of small 
fragments.  Following precipitation and SfiI digestion, cDNA was ligated overnight to 
LMN8iresZeo (an MLV vector with a zeocin resistance gene translated via an internal 
ribosomal entry site).  To assess library complexity, 10% of the ligation was transformed 
and serial dilutions were plated.  The remaining ligation was transformed and grown 
under selection in soft agar for 72 hours. 
 Virus stocks used to transduce CHO-PGSA cells with the HeLa cDNA library 
were titrated by infection of 10
5
 CHO-PGSA cells per well on 12-well plates with a 5-
fold serial dilution of virus.  The following day, infected cells were re-plated on 100mm 
dishes and 200!g/mL zeocin was added that evening.  Cell foci were counted 10 days 
later to determine the number of infectious units per unit volume of the virus stock 
solution (IU/mL).  An MLV vector expressing a neomycin resistance gene under a CMV 
promoter (CN) was used to generate CERV2 enveloped particles for the first round of 
library screening.  CN was constucted by the removal of CMV-DsRED from CNCR 
using BstBI/NotI, followed by klenow treatment and blunt-ended ligation.  CERV2 
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enveloped virions carrying CN or LHCX (a Clontech MLV vector expressing a 
hygromycin resistance gene) were titrated on HeLa cells using 1!g/mL G418 or 
100!g/mL hygromycin, respectively, in a fashion similar to the cDNA library titration. 
 CHO, PGSA, and all derivatives were cultured in ham’s F12 media supplemented 
with 10% fetal bovine serum and 1mM glutamine.  Pan troglodytes verus skin fibroblasts 
AG06939 (Coriell) were grown in MEM alpha with 20% fetal bovine serum and 2mM 
glutamine.  MT2 and CEMSS cells were grown in RPMI with 10% fetal bovine serum 
and 2mM glutamine.  All other cell lines were grown in DMEM supplemented with 10% 
fetal bovine serum.  All media was supplemented with 10!g/mL gentamycin.  The CHO-
CTR1 and PGSA-CTR1 cell lines were generated by cloning CTR1 into LNCX2 (a 
Clontech MLV vector containing an LTR-driven neomycin resistance gene and a 
multiple-cloning site proceeded 3’ of a CMV promoter) or LNCX2 constructs containing 
an HA tag before or after the multiple-cloning site using XhoI and NotI (forward primer: 
5’- TATATACTCGagATGGATCATTCCCACCATATGG -3’ reverse primer: 5’- 
TATATAGCGGCCGCTCAATGGCAATGCTCTGTGATATCC -3’).  In the case of 
CTR1 mutant constructs, PCR products were first cloned using XhoI and NotI into 
PCR3.1 (Invitrogen) containing an HA tag sequence 5’ to the cloning site and then 
subcloned to LNCX2 using SnaBI and NotI.  Hamster CTR1 was amplified from CHO 
cDNA using primers designed against untranslated regions that are conserved between 
mouse and rat CTR1 (forward primer: 5’- 
TATATACTCGagGGGATCCAGTTCTGagAGGAAGAC -3’ reverse primer 5’- 
TATATAGCGGCCGCAGACAGGagAGagRAGGGATGATTGG -3’).  Following 
XhoI/NotI cloning into pCR3.1 and sequencing, primers were designed to amplify only 
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the open reading frame of hamster CTR1 (forward primer: 5’- 
TATATACTCGagATGGGGATGAACCATATGGGC -3’ reverse primer 5’- 
TATATAGCGGCCGCCTTAATGGCAATGCTCTGTGATGTCC -3’) and this product 
was cloned into LNCX2 using XhoI and NotI.  VSV-G enveloped MLV pseudotypes 
were used to transduced CHO or PGSA cells prior to selection with 1mg/mL G418. 
 
Full-length HIV-1  
 A pNL4.3 HIV-1 provirus that lacked Vpr expression due to both a start codon 
mutation and the introduction of a stop codon (both silent in the Vif open reading frame) 
was provided by Stuart Neil.  Vif expression was disrupted in this construct by the 
introduction of both a 13-nucleotide deletion and an in-frame stop codon to the region 
immediately following the end of the GagPol open reading frame.  This was done by the 
amplification of a region from the AgeI restriction site in Pol to the border of the Vif 
deletion and a second region from the end of the Vif deletion to the EcoRI restriction site 
in Vpr.  The primers were designed to generate products that contained a 29 nucleotide 
overlapping sequence that included the introduced Vif mutations (sense primer: 5’- 
GTAAAACACCATATGAAGCTTAGGACTGGTTTTATAGAC -3’ and antisense 
primer: 5’- CCAGTCCTAAGCTTCATATGGTGTTTTACTAATCTTTTCCATGTG -
3’).  Following an overlapping PCR that included the products of the first PCRs as 
templates and external primers, the final PCR product was gel-purified and cloned into 
the parental pNL4.3 delta Vpr using AgeI and EcoRI.  Next, in order to acquire an eGFP 
reporter, SalI and SpeI were used to sub-clone both the deltaVpr and deltaVpr/deltaVif 
genotypes into an HIV-1 proviral plasmid that expressed NL4.3 GagPol, HXB-2 
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envelope, and eGFP in place of Nef (previously derived from pNL/HXB and R7/3/GFP 
(258, 259)).  Virus stocks were generated by PEI transfection of 293T cells on 100mm 
dishes using 5µg of proviral plasmids.  The resulting viruses are referred to in the text as 
Vif+ and #Vif.   
  
Endogenous capsid sequence retrieval 
 To identify MLV-related viruses in primate genomes, the amino acid sequence of 
the capsid N-terminal domain of moloney murine leukemia virus was used in a 
TBLASTN search of the chimpanzee genome (http://www.ensembl.org).  After retrieving 
all complete TBLASTN hits, the sequences were separated into two families, 
corresponding to CERV1 and CERV2, according to sequence homology and length.  
After removing redundant sequences, ClustalW was used to obtain nucleotide and amino 
acid consensus sequences for both CERV1 and CERV2 capsid N-terminal domains (CA-
NTDs).  The same method was used to find homologues of CERV1 and CERV2 CA-
NTDs in Macaca mulatta (RhERV1 and RhERV2, respectively).  RhERV1 CA-NTDs 
included two phylogenetically distinct subgroups, termed RhERV1a and RhERV1b, and 
two independent consensus sequences were derived.  Similarly, CA-NTD sequences from 
enMLV were retrieved from the C57BL/6J genomic database.  A phylogeny was 
reconstructed for all capsid NTDs using ClustalX1.8 and phylogenetic trees were drawn 
using Figtree.   
 Individual CA-NTD amino acid sequences were used in TBLASTN searches and 
regions positioned immediately 3’ to precise hits were inspected for Env-like sequences. 
The moloney MLV was used to assist in the definition of a theoretical 
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CERV1/CERV2/RhERV1/RhERV2 open reading frames. To define a consensus 
envelope sequence for each endogenous retrovirus family, a single envelope amino acid 
sequence was used as a TBLASTN query.  All resulting envelope sequences were aligned 
to derive a consensus sequence, regardless of their linkage to a previously retrieved 
capsid sequence. Analyses of the CA-linked envelope genes were then performed as for 
the CA-NTD sequences.  In the case of RhERV2, two distinct groups of envelope 
sequences were observed and separate alignments and consensus sequences were derived 
for each subgroup of envelopes.  Similarly, three distinct enMLV envelopes were 
grouped according to the previously defined tropisms of these viruses: polytropic, 
modified polytropic, and xenotropic (72).  In the case of CERV1, because of the large 
numbers of unique CA-NTD sequences, the analysis was confined to two groups of 10 
CA-NTDs that were each used to define linked Env sequences.  One CA-NTD group had 
zero or one G to A mutations, and a second group had "4 G to A mutations. 
 Because of the small number of CERV2 integrations in the chimpanzee germ line, 
all CERV2 proviral sequences were compiled.  Flanking regions 1500 nucleotides 5’ and 
8000 nucleotides 3’ to the capsid NTDs were aligned.  Four of the proviruses aligned for 
8293 nucleotides with pairwise identity scores of at least 83%.  Therefore, those portions 
of sequence were trimmed and defined as full length CERV2 provirus.  Six additional 
incomplete proviruses were defined.  One database derived proviral sequence was 
excluded because a 99.9% sequence identity with another locus made it unlikely to be an 
independent retroviral integration, and is instead likely to be either a genomic duplication 
or an error in the compiling of genomic sequence. 
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Generation of endogenous retrovirus CA-NTD/MLV chimera libraries 
 A library of chimeric GagPol plasmids was generated that contained MoMLV 
GagPol with the capsid NTD replaced with that from endogenous retroviruses.  Genomic 
DNA was isolated using standard protocols from Pan troglodytes verus skin fibroblasts 
AG06939 (Coriell), Macaca mulatta 221 cells, and NIH 3T3 cells and used as PCR 
template. Primers were designed to anneal to the capsid NTD consensus sequences 
described above.  Because of relatively high conservation at the 3’ end of the capsid 
NTD, the same reverse primer was used for all endogenous retrovirus families: 5’- 
TACYTTRGCCAAATTRGTRGG -3’.  The 5’ primers were specific to each virus 
family and all contained a BsmI restriction site: CERV1: 5’- 
CTCGCAGGCATTCCCCCTTCGGGAAATAGG -3’; CERV2: 5’- 
CTCGCAGGCATTCCCCCTCCGCACCGTG -3’.  To amplify capsid genes from the 
Rhesus macaque and mouse genomes, primers were designed to anneal to a p12 region 
immediately 5’ of the capsid- RERV1a: 5’- 
CAGCYGCCTGACTCYAYGGTGGCATTCCCCCTT -3’; RERV1b: 5’- 
CRACTCCCTGACTCCACYGTGGCATTCCCTCTC -3’; RERV2: 5’- 
CCTTCYACTTGGCAATCCTCGGCATTCCCCCTC -3’; and enMLV: 5’- 
GCRGAYTCCACCWCCTCYCRGGCATTCCCACTC -3’.  A small fragment was 
amplified from MLV GagPol using the reverse complement of the capsid NTD 3’ primer: 
5’- CCYACYAATTTGGCYAARGTA -3’; and a primer annealing in the MLV capsid 
C-terminal domain: 5’- CTTCTAACCTCTCTAACTTTCTCC -3’.  The amplified 
portion of the MLV GagPol plasmid was engineered to contain an AfeI restriction site.  
Thereafter, an overlapping PCR product was generated that included the amplified 
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endogenous virus capsid NTDs and the MoMLV capsid CTD fragment. This PCR 
product was cloned into the MLV GagPol plasmid using BsmI and AfeI restriction 
enzymes.  The resulting chimeric GagPol plasmids were isolated and screened for 
functional capsid genes by cotransfection with an MLV-based vector containing GFP and 
VSV-G envelope using polyethyleneimine (PEI) in 293T cells.  Supernatant from these 
cells were used to infect hamster CHO-KI-derived cells.  Two days post-infection, cells 
were trypsinized, fixed in 2% PFA and subjected to FACS analysis using a Guava 
Easycyte to determine the percentage infected (GFP-positive) cells.  To measure 
TRIM5", TRIMCyp and Fv1 sensitivity, Mus dunni tail fibroblasts (MDTF) or MDTF 
stably expressing human TRIM5", chimpanzee TRIM5", rhesus macaque TRIM5", 
African green monkey TRIM5", owl monkey TRIMCyp, Fv1N, Fv1B, or Fv1NB that have 
previously been described (108, 121) were infected in the presence of 5µg/mL polybrene. 
GFP-positive cells were quantified by FACS analysis two days post-infection. 
 To determine whether the E91K mutation in the RhERV2 CA-NTD modulates its 
sensitivity to human and chimpanzee TRIM5", this point mutation was introduced by 
PCR into a chimeric MLV GagPol plasmid containing a consensus RhERV2 CA-NTD 
sequence.  Additionally, to determine whether the CA-CTD altered CERV1 sensitivity to 
TRIM5", a CERV1 CTD sequence, as described in Kaiser S.M. et al. (260), was 
synthesized using as series of overlapping ~60 nucleotide oligonucleotides.  The resulting 
product was then used in an overlapping PCR reaction with the CERV1 CA-NTD 
consensus sequence and this full-length capsid was cloned into the MLV GagPol 
plasmid.  In order to match the CERV1 CA-NTD consensus to the ancestral sequence 
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described in Kaiser et al.(260), the R35Q mutation was also introduced using PCR-based 
mutagenesis into this CERV1 full-length capsid/MLV chimera.   
 
Sequence analysis 
 Mutations and their dinucleotide sequence contexts were quantified using 
Hypermut (http://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html).  We 
generated fasta alignments using MacVector to use as input for Hypermut and the 
consensus sequence for each virus family (described above) was used as a reference 
sequence.  The Hypermut output provided the total number nucleotide changes (each 
insertion/deletion was reduced to a single nucleotide change in MacVector) as well as the 
number of G to A mutations relative to the consensus sequence.  Hypermut also provided 
the number of G to A changes that occurred in each of the four possible dinucleotide 
contexts when the nucleotide immediately 3’ to the G (or the +1 position) in the 
consensus sequence is considered (i.e. GG, GA, GC and GT).  To quantify the -1 position 
for C to T changes, the +1 position for C to T changes, and the -1 position for G to A 
changes, the reverse complement, complement, and reverse of each alignment was 
generated respectively and used as Hypermut inputs.  The latter two analyses allowed us 
to quantify the number of C to T and G to A changes occurring in CG dinucleotides.  We 
repeated this analysis, after removal of G to A and C to T changes occurring in CG 
dinucleotides.  In some charts, the percentages of G to A or C to T changes that were in 
each dinucleotide context were normalized according to the dinucleotide composition of 
a given consensus sequence.  P-values were calculated for these data using a chi-square 
goodness of fit statistical test.   
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Gene Synthesis 
 ClustalW alignments and majority consensus sequences of CERV2 Gag, CERV1 
envelope, CERV2 envelope, and RhERV2 envelope were derived using MacVector.  All 
envelope sequences were collected from Ensembl using TBLASTN according to their 
homology with MoMLV protein sequences first and then CERV consensus sequences 
were used to blast the rhesus macaque genome to ensure the recovery of all homologues.  
Sequences flanking the CA-NTDs used in the hypermutation analysis described above 
were aligned with MoMLV Gag to define a CERV2 Gag open reading frame.  As 
described in the next chapter, a second version of CERV2 Gag was also designed that 
included protease cleavage sites that matched those from MLV Gag (CERV2/MLVGag).  
Overlapping oligonucleotides were designed using Genedesign from Johns Hopkins 
University (http://slam.bs.jhmi.edu/gd).  The target oligonucleotide length and overlap 
melting temperature was set to 60 nucleotides and 56°C, respectively.  EcoRI and NotI 
sites were added to oligonucleotides designed to construct the 5’ and 3’ ends of the 
envelope genes for cloning into the PCAGGS vector (BCCM).  In the case of CERV2 
Gag, the 5’ end was also designed for EcoRI recognition and at the 3’ end, 20 nucleotides 
were designed to overlap with the 5’ end of MLV Pol (forward primer: 5’- 
GagGagGAATTCATGGGACAGACTCTGACGAC -3’ reverse primer: 5’- 
CTCCTGACCCTGACCTCCCTAATCGCTGTCCTCTCCCAGGGTCAGGACCGGGG
TGGGTTTCTTCC -3’).  Primers used to amplify MLV Pol introduced 20-nucleotides at 
the 5’ end that overlapped with the 3’ end of CERV2 Gag and a NotI restriction site was 
introduced at the 3’ end (forward primer: 5’- 
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CCTGGGagAGGACAGCGATTAGGGagGTCAGGGTCAGGag -3’ reverse primer: 5’- 
TATATAGCGGCCGCTTAGGGGGCCTCGCGGGTTAACC -3’). 
 For envelope gene construction, two sequential polymerase chain reactions were 
carried out.  The first contained a mixture of the overlapping oligonucleotides prepared 
by combining 1!L of each 100!M stock solution and then diluting ten-fold.  A 50!L 
PCR reaction contained 3!L of the diluted oligonucleotide mixture and gene synthesis 
was carried out for 20 cycles using Phinzymes Phusion (1 min. 98°C, 1 min. 50°C, and 2 
min. 72°C).  The second PCR contained 2!L of crude product from the first in a 50!L 
reaction with 200nM external primers.  Amplification proceeded for 25 cycles (1 min. 
98°C, 1 min. 55°C, and 2 min. 72°C) and the resulting product was gel-purified using the 
Qiagen gel extraction kit and cloned into PCAGGS with EcoRI and NotI.  Sub-cloning 
between individual clones was necessary to eliminate errors in CERV1 envelope using 
SpeI and RhERV2 envelope using DraI. 
 To construct the CERV2 Gag consensus fused to MLV Pol, first, the Gag was 
synthesized much the same way as was described above for envelope genes except, due 
to lower yields, there were a few protocol changes.  The PCR buffer used in a 20-cyle 
assembly PCR was supplemented with 3mM MgCl2 and then 3!L of this PCR was 
subjected to 15 cycles of amplification using external primers.  A 1.8kb product was gel-
purified for use in a third PCR that ran for 20 cycles.  The resulting product was gel-
purified and used in an overlapping PCR with MLV Pol.  The two templates were used at 
equal ratio in 3% DMSO for a Phusion catalyzed, twenty-cycle reaction (1 min. 98°C, 1 
min. 70°C, and 1.5 min. 72°C).  After a final Qiagen gel-purification, the CERV2Gag-
MLVPol PCR product was cloned into PCAGGS using EcoRI and NotI.  To eliminate 
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errors, sub-cloning was completed using KasI and NheI for CERV2 Gag and XhoI for 
CERV2/MLV Gag. 
 
APOBEC restriction assays 
 Human and rhesus macaque APOBEC3G with an N-terminal Myc tag was 
expressed from previously described pCR3.1 constructs (156). For comparative purposes, 
chimpanzee APOBEC3G was amplified from a pcDNA3.1 construct provided by 
Nathaniel Landau (261) and used to replace human APOBEC3G in pCR3.1-Myc using 
EcoRI and NotI.  All other human APOBECs were expressed with C-terminal HA tags 
from previously described pCMV4 constructs (160).  Virions were produced in the 
presence or absence of APOBEC proteins by cotransfection of 293T cells on 24-well 
plates with 300ng of the indicated GagPol, 300ng CNCG (or CSGW with HIV GagPol), 
100ng VSV envelope, and variable amounts of APOBEC as indicated.  Empty pCR3.1 
was used to normalize the total amount of DNA in each sample.  The resulting virions 
were used to infect MDTF cells overnight with 5µg/mL polybrene and, as before, 
infection was evaluated according to GFP expression using the Guava Easycyte.  Lysates 
from virus-producing cells were ran onto 4-12% NuPAGE Bis-Tris gels (Invitrogen) and 
protein was transferred to nitrocellulose membranes followed by probing with an 
antibody against MLV capsid (262).   
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HIV evolution in vitro 
 The infectious titer of both initial viral stocks and supernatent from infected T-cell 
lines was measured using the same general protocol.  10
4
 MT2 or CEMSS cells were 
seeded in 100µL in each well on a 96-well plate.  Five, five-fold serial dilutions were 
prepared and 50µL of each were added to cells.  Following an overnight infection, further 
rounds of replication were prevented using 100µg/mL dextran sulfate, a cell-entry 
inhibitor (263).  At two days post-infection (dpi), cells were fixed in 2% 
paraformaldehyde and GFP-positive cells were quantified by FACs.   
 Prior to selection, HIV-1 Vif+ or #Vif (described above) were grown in MT2 or 
CEMSS cells.  In 25cm
2
 tissue culture flasks, 5x10
5
 cells were infected with 500IU in 
6mL of total volume and left overnight before a two-fold dilution with fresh media.  At 4 
dpi (days post infection) 10mL fresh media was added and at 6 dpi cells were transferred 
to 75cm
2
 flasks with 40mL fresh media.  Cells were split 1:3 every three days.  To 
maintain the MT2/Vif+ culture during virus-induced cell death, uninfected MT2 cells 
were added at follows: 5x10
5
 cells at 4 dpi, 10
6
 cells at 6 dpi and 8 dpi, 3x10
6
 cells at 10 
dpi, and 4x10
6
 cells at 13 dpi.  In the case of both CEMSS infected cultures, 10
6
 CEMSS 
cells were added at 8 dpi and 10 dpi and then an additional 4x10
6
 cells at 12 dpi.  100µL 
aliquots were fixed periodically in 2% paraformaldehyde and stored at 4°C.  Fifteen days 
after infection, 50mL of each culture were spun on a tabletop centrifuge at 3000rpm for 
15 minutes.  The resulting supernatent was filtered through 0.22µm filters and 1.25mL 
aliquots were frozen at -80°C for further analysis.  Cells were washed in PBS and their 
genomic DNA was extracted for PCR using the Qiagen DNeasy kit.   
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 To amplify sequences packaged into virions, viral RNA was extracted from 
pelleted virus.  In Beckman 14x89mm polyallomer centrifuge tubes, 6mL of filtered T 
cell supernatent was gently layered on top of 4mL of PBS with 20% sucrose.  Samples 
were spun at 27000rpm in a Beckman ultracentrifuge for two hours at 4°C.  The 
supernatent was aspirated to ~250µL and this remaining volume was shook from the 
tubes before allowing them to drain upside down for several minutes.  The walls of the 
tubes were dried with kimwipes.  Virions were resuspended in 100µL PBS by first 
incubating on ice for 90 minutes and then pipetting up and down 50 times.  RNA was 
extracted using the Qiagen viral RNA mini kit and cDNA was prepared using the 
Invitrogen Superscript III kit and oligo-dT primers.  Both this cDNA and the genomic 
DNA from infected CEMSS and MT2 cells were used as PCR template to amplify the 
polymerase domain of HIV-1 reverse transcriptase (forward primer: 5’- 
CACTTTAAATTTTCCMATTAGTCCTATT -3’ reverse primer: 5’- 
TGGCAGCACTATAGGCTGTACTG -3’).  The resulting products were gel purified and 
cloned using the Invitrogen TOPO zero-blunt cloning kit.  Plasmid clones were 
sequenced using the Genewiz SP6 primer.   
 AZT, nevirapine, nelfinavir, and 3TC (provided by the NIH reagent program) 
were all dissolved in DMSO to 100mM.  Drugs were titrated in T cell lines by first 
infecting four sets of 10
6
 CEMSS or MT2 cells with HIV-1 Vif+ at MOI 0.001 in 5mL 
(eight infections total).  After an overnight incubation, cells were split into 12 wells on 
24-well plates in media with or without varying concentrations of each drug in 1mL per 
well.  Cells were collected at various time points by fixing 100µL in 2% PFA for later 
quantitation of GFP+ cells.  Cells were split 1:5 every four days with each drug 
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concentration maintained.  Selection using patient plasma was done in the same fashion 
as the drug titrations, in the 24-well format to conserve plasma.  The patient blood sample 
was collected in heparin-coated tubes.  After inactivation at 57°C for 30 minutes, 30µL 
aliquots of blood plasma were prepared to avoid any additional freeze-thaw cycles after 
storage at -80°C. 
 Selections in MT2 cells using AZT and/or nevirapine were done by infecting 
4x10
6 
cells at 0.001 MOI in 25cm
2
 tissue culture flasks with supernatants (Vif+ or #Vif) 
collected at 15 dpi from MT2 cells (described above).  One day after infection, cells were 
split into plain media or media containing 4µM AZT, 4µM nevirapine, or a combination 
of 4µM AZT and 500nM nevirapine.  Cultures were split 1:5 every four days and enough 
fresh drug was added to maintain a constant drug concentration with the conservative 
assumption that no active drug still remained in the culture.  This was done to prevent a 
gradual decrease in drug concentration as degradation occurred over long periods of time.  
The MT2 culture infected with Vif+ and lacking drug was maintained by the addition of 
cells every three to four days (or when significant cell death was apparent).  Selection 
using nevirapine in CEMSS was carried out in the same fashion except with a different 
initial procedure.  2x10
6
 CEMSS cells were infected at 0.002 MOI with supernatent 
collected from MT2 or CEMSS cells infected 15 days prior with Vif+ or #Vif virus.  At 3 
dpi, 500nM nevirapine was added to half of the infected cells. 
 
Receptor Screen 
 Twenty pools of 2x10
5
 PGSA were transduced with the HeLa cDNA library (MOI 
0.5) one day after plating in 6-well dishes.  Cells were expanded to 15cm dishes the 
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following day and selection with 200!g/mL zeocin began that evening.  Each pool was 
grown under selection for six days before plating in duplicate at 10
5
/well on a 12-well 
dish.  The following day, cells were infected with CERV2 enveloped virions carrying a 
CMV-Neo MLV vector (MOI 3.5).  One uninfected and two minus-library controls were 
carried forward in parallel.  Each of the 43 groups of cells were expanded to 100mm 
dishes one day after infection and one day prior to the addition of 1mg/mL G418.  
Following ten days of G418 selection, colonies were pooled as 20 separate groups 
corresponding to the original 20-pool PGSA cell expression library. 2.5x10
4
 cells from 
each of these colony pools were infected independently with CERV2 enveloped LHCX 
virions in a 48-well plate (MOI 1.0).  One day after infection, cells were transferred to 6-
well plates and then placed under selection with 100!g/mL hygromycin on the following 
day.  Genomic DNA was extracted from surviving cells using the Qiagen DNeasy kit and 
used as PCR template with primers designed to anneal to DNA flanking the 
LMN8iresZeo cloning site (forward primer: 5’- ATACACGCCGCCCACGTGAAGG -3’ 
reverse primer 5’- GCTTCCTTCACGACATTCAACAGACC -3’).  The resulting 
products were cloned using the Invitrogen TOPO zero-blunt cloning kit and four colonies 
from each were sequenced using the SP6 primer.  
 
Virion Binding 
 GFP-labeled virus particles were generated by overnight PEI co-transfection of 
293T cells with 5!g MLV Gag-GFP expression plasmid (a gift from David Perez-
Caballero) and 5!g PCAGGS-CERV2envelope or 5!g PCAGGS on 100mm dishes.  The 
virion-containing supernatant was harvested two days post-transfection and purified 
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through a 0.22!m filter.  CHO cells or a single-cell clone of CHO-humanCTR1 were 
seeded two days prior to binding onto a poly-lysine coated 15mm coverslip within a 
35mm dish at 10
5
 cells/dish.  Cells to be used for virion binding in the presence of copper 
were incubated with 20!M CuCl2 for two hours at 37°C.  All cells were then incubated in 
media containing 20mM HEPES pH 7.2 at 4°C for 20 minutes.  980!L virion-containing 
supernatent was supplemented with 20mM HEPES pH 7.2, 5mg/mL polybrene, and 
20!M CuCl2 or water in 1mL of total volume, applied to aspirated cells at 4°C, and 
incubated at 4°C for one hour.  The cells were washed three times with filtered PBS at 
4°C before fixation for 20 minutes at room temperature with 4% paraformaldehyde.  The 
cells were then washed twice with PBS. 
 
RNA-interference 
 A Dharmacon siGENOME smart pool was used to knockdown CTR-1 and 
included RNA designed to target the following sequences within the CTR1 open reading 
frame: 5’-AGGCAGUGGUAGUGGAUAU-3’, 5’-CUGCGUAAGUCACAAGUCA-3’, 
5’-GGAACCAUCCUUAUGGagA-3’, and 5’-CAUAUGGGGAUGagCUAUA-3’.  Cells 
were seeded on 24-well dishes 24 hours prior to transfection at 10
5
cells/well.  Media was 
replaced with Gibco Optimem 2 hours prior to transfections and then again 20 minutes 
before transfections.  Invitrogen Lipofectamine 2000 was used to co-transfect cells with 
10pmol of pooled siRNA and 300ng of DsRED expression plasmid (transfection 
efficiency marker) according to the manufacturer’s instructions.  Following 6 hours of 
transfection, cells were supplemented with 1mL DMEM 10% FBS without antibiotics.  
The transfection was repeated the following day. One hour after the addition of fresh 
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media to the second transfection, cells were trypsinized and seeded on a 96-well plate at 
10
4
cells/well for infection the following day. To validate RNAi activity, transfections 
were repeated as described above except 500ng of PCR3.1-HA-CTR1 was included in 
the first of two siRNA transfections.  Cells were collected for western blot in SDS-PAGE 
loading buffer two days after the first transfection. 
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Chapter III.  Were TRIM5 and APOBEC3 proteins capable of 
restricting CERV1 and CERV2? 
 
 
CERV1 and CERV2 capsid N-terminal domains 
 To investigate the host range limitation and extinction of chimpanzee endogenous 
retrovirus groups one and two (CERV1 and CERV2), it was first determined whether 
TRIM5 restriction factors could have been capable of targeting them during their 
exogenous replication.  Toward this purpose, we studied CERV1 and CERV2 capsid N-
terminal domain (CA-NTD) sequences found in the chimpanzee genome as well as their 
homologues in the rhesus macaque (RhERV1 and RhERV2).  The CA-NTD appears to 
contain all determinants of TRIM5" recognition; this is intuitive given that its highly 
conserved structure comprises the surface of the retroviral core, which is exposed to 
TRIM5" following entry into a target cell (108-111, 113, 114).  Therefore, CERV1 and 
CERV2 CA-NTDs in the context of functional chimeric virions are sufficient to test 
whether TRIM5" was able to restrict these viruses.  An ability to target CERV1 and 
CERV2 capsids would indicate that TRIM5" proteins could have been capable of 
restricting transmissions during their exogenous replication.  The use of a minimal 
portion of the endogenous retroviruses also increased the likelihood of including intact 
and functional open reading frames from proviruses that contained frequent mutations.  
Endogenous murine leukemia viruses (enMLV) were also included for comparison.   
 All sequences were compiled by BLAST searches of the Pan Troglodytes, 
Macaca mulatta and Mus musculus genome sequence databases and were then used to  
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Figure 6. Phylogenetic tree of ancient primate gammaretroviral capsid NTDs. A sequence 
alignment, and phylogeny of all capsid NTDs from CERV1, CERV2, RhERV1a, RhERV1b, 
RhERV2, and enMLV and various prototype gammaretroviruses was generated using ClustalX 
software. The tree diagram was generated and edited using FigTree software.  
 
 
derive group-specific capsid consensus sequences.  A phylogeny of all retrieved 
endogenous CA-NTDs, as well as those from several other gammaretroviruses, was 
constructed (Figure 6).  A monophyletic group of 85 unique CERV1 CA-NTD sequences 
was found in the chimpanzee genome, which were closely related to 48 sequences found 
in the rhesus macaque (RhERV1a).  A second, more distant group of 28 CERV1 
homologues was also compiled from the rhesus macaque genome database and termed 
RhERV1b.  CERV2, which is more closely related to moloney MLV than CERV1, 
includes ten CA-NTD sequences in the chimpanzee genome and 44 orthologues in the 
rhesus macaque (RhERV2).  CERV2 and RhERV2, based on their capsid sequences, 
appear to be closely related to the baboon endogenous retrovirus (BaEV).  The mouse 
genome database contained 41 unique MLV CA-NTD sequences that are from three 
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groups of endogenous retroviruses (enMLV) previously described as xenotropic, 
polytropic, and modified polytropic MLV (72). 
 
MLV Chimeric Viruses containing primate and mouse endogenous 
gammaretroviral CA-NTDs are generally resistant to TRIM5! proteins 
 To test ancient retroviruses for sensitivity to TRIM5 proteins, functional virions 
were constructed that contained CA-NTDs from endogenous retroviruses.  Libraries of 
chimeric MLV GagPol were constructed by amplifying CA-NTDs from chimpanzee, 
rhesus macaque, and mouse genomic DNA and cloning the resulting products in place of 
the native MLV CA-NTD.  It is possible that diversity in such a library is not only the 
result of natural sequence variations, but could also contain contributions from 
recombination of highly similar sequences or DNA polymerase errors during PCR.  
Therefore, in order to be conservative, only sequences that perfectly matched those found 
in the sequence database were included in the experiments below. 
 Mus dunni tail fibroblasts (MDTF), that were either unmanipulated or made to 
stably express TRIM5" proteins, were infected with MLV virions carrying recombinant 
GagPol proteins.  MDTF were chosen due to the lack of a TRIM5" gene in mice.  The 
CA-NTD of the TRIM5" resistant moloney MLV GagPol was replaced with that from N- 
or B-tropic MLV, or with endogenous retroviral CA-NTDs.  The resulting recombinant 
MLV particles also carried a minimal MLV genome encoding a GFP reporter and were 
enveloped with VSV-G to allow efficient infection of MDTF.  This system allowed for 
only a single cycle of replication and infections were quantified based on the percentage 
of MDTF expressing GFP. 
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 As expected, MLV particles carrying the CA-NTD from an N-tropic, but not B-
tropic, MLV were restricted by the human, chimpanzee, African green monkey TRIM5" 
proteins and also, to a lesser degree, by the rhesus macaque TRIM5".  These restricted 
infections served as controls to demonstrate the functionality of the stably expressed 
TRIM5" proteins, as well as to confirm that swapping the CA-NTD was sufficient to 
confer TRIM5" sensitivity.  Virions containing CA-NTDs that matched the majority 
consensus sequence of CERV1 and CERV2 were both infectious (~10
4
 IU/mL) and were 
not restricted to any degree by human, chimpanzee, rhesus macaque, or African green 
monkey TRIM5", or by owl monkey TRIM-cyclophilinA (Figure 7A).  It should be 
noted that these results are in sharp contrast to those reported by Kaiser et al., in which 
both an ancestral CERV1 full-length capsid (both NTD and CTD) and p12 were included 
in an MLV chimera and this virus was restricted by human and chimpanzee TRIM5".  
Aside from including a larger portion of CERV1, the ancestral CERV1 capsid used by 
Kaiser et al. differed by one amino acid from the CERV1 consensus CA-NTD used here 
(glutamine instead of arginine at position 35).  To address this discrepancy, recombinant 
MLV GagPol genes were constructed that contained full-length CERV1 capsids with 
either the ancestral or majority consensus sequences.  Importantly, inclusion of the entire 
CERV1 CA did not confer any TRIM5" sensitivity to the chimeric MLV virions (Figure 
7B).  Furthermore, TRIM5" resistance was observed regardless of whether the consensus 
or the ancestral CERV1 capsid was used (glutamine or arginine at residue 35, 
respectively). 
 MLV recombinants containing consensus CA-NTDs as well as several functional 
variants from CERV1, CERV2, RhERV1a, RhERV1b, RhERV2 and enMLV were tested 
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for sensitivity to TRIM5 proteins as well as to the murine capsid-dependent restriction 
factors, Fv1
N
 and Fv1
B
 (Figure 7C, D).  As was described above for particles containing 
consensus CERV1 and CERV2 CA-NTDs, nearly all chimeric MLV pseudotypes tested 
displayed resistance to restriction by a variety of primate TRIM5" proteins and owl 
monkey TRIM-Cyp.  In addition, all primate endogenous CA-NTDs were also insensitive 
to Fv1.  With the exception of one variant, the enMLV CA-NTDs conferred a B-tropism 
to recombinant particles in that they were sensitive to Fv1
N
 and Fv1
NB
, but insensitive to 
Fv1
B
 and TRIM5 proteins.   
 Only one ancient CA-NTD displayed a TRIM5-sensitive phenotype.  This 
exception to the general TRIM5 resistance observed in all other recombinants was an 
MLV/RhERV2 recombinant (#58) that was restricted by chimpanzee TRIM5" and 
marginally by human TRIM5", but was insensitive to rhesus macaque TRIM5" (Figure 
7E).  This particular RhERV2 CA-NTD contained four amino acid differences relative to 
the RhERV2 consensus; one of which, E91K, was not carried by any of the other 
RhERV2 CA-NTDs tested. On the MLV CA-NTD structure, residue 91 is predicted to lie 
on the exterior face of the mature core, making it a reasonable putative determinant of 
TRIM5" sensitivity (Figure 7F).  Indeed, when the E91K mutation was introduced into 
the RhERV2 consensus CA-NTD, the resulting MLV recombinant displayed the same 
TRIM5" sensitivity as variant #58 (Figure 7E).  Therefore, residue 91 is a novel 
determinant of TRIM5" restriction.  Interestingly, the E91K mutation is shared by ~20% 
of all RhERV2 capsids reported in the genome database, but it is not found in CERV2.  
This, coupled with the observation that the E91K mutant displayed sensitivity to 
chimpanzee but not rhesus macaque TRIM5", suggests that a selective pressure may  
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Figure 7. Resistance of chimeric MLVs containing primate gammaretroviral CA-NTDs to 
primate TRIM5 proteins A) MLV chimeric viruses encoding CA-NTD consensus 
sequence from CERV1 and CERV2 were used to infect MDTF cells expressing human, 
chimpanzee, rhesus or African green monkey TRIM5" or Owl Monkey TRIMCyp 
proteins. GFP positive cells were quantified by FACS (Guava EasyCyte) 48h after 
infection. N-MLV and B-MLV were used as controls. B) MLV chimeric viruses 
containing an entire ancestral CERV1 capsid sequence (CERV-1(anc)), an entire 
consensus CERV1 capsid sequence (CERV1(con)) or a consensus CERV1 CA-NTD 
fused to an MLV CTD (as in A) were used to infect MDTF cells expressing the indicated 
TRIM5 proteins. N-MLV and B-MLV were used as controls and infection was evaluated 
as in A). C) MLV-chimeric viruses encoding natural variant CA-NTDs from CERV1, 
RhERV1a, or RhERV1b were used to infect MDTF cells expressing various TRIM5 and 
Fv1 proteins. D) MLV-chimeric viruses encoding natural variant CA-NTDs from 
CERV2, RhERV2 and enMLV were tested as in A). E) MLV chimeric viruses encoding a 
consensus RhERV2 CA-NTD, a natural variant CA-NTD that includes the E91K 
mutation (RhERV2 58), or an E91K point mutant were tested as in A). F) Representation 
of the MLV CA-NTD with the positional equivalent of the RhERV2 E91 residue colored 
red. The left picture shows a side view of the CA-NTD monomer (outer surface of the 
capsid at the top) while the right picture shows a view of a single CA-NTD hexamer, 
viewed from the outside of what would be a complete core. 
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have existed in the chimpanzee lineage that was able to prevent the transmission and/or 
emergence of this particular mutation.   In general, though, the TRIM5" resistance 
displayed by all the other CA-NTD variants tested suggests that it is unlikely that 
TRIM5" was able to impose complete transmission barriers against the CERV1 and 
CERV2 families.  In particular, the human TRIM5" displayed only marginal activity 
against RhERV2 capsids carrying the E91K mutation and was completely inactive 
against all others, which argues against a general protective role for human TRIM5" 
during potential transmissions of CERV1 and CERV2 to the human lineage. 
 
Evidence of endogenous gammaretrovirus restriction by APOBEC3 family 
members 
 Several APOBEC3 cytidine deaminases are capable of restricting retrovirus 
replication and a hallmark of their activity is the production of G to A hypermutation 
within specific sequence contexts.  A Bias in CERV1 and CERV2 sequence variability 
toward these APOBEC3-associated mutations would suggest that these viruses were 
subject to just such an activity during their exogenous replication.  This would suggest a 
potential role for APOBEC3 restriction factors in the extinction and/or inter-species 
transmissions of exogenous CERV1 and CERV2. In order to search for signs of past 
APOBEC3 activity, majority consensus sequences were derived for CA-NTDs from 
CERV1, RhERV1a, RhERV1b, CERV2, RhERV2, and enMLV.  Within each of these 
groups, any deviation from the consensus sequences was documented.  A striking degree 
of conservation was observed in all groups of CA-NTDs with a typical divergence from a 
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given majority consensus sequence of <3%.  In several groups, though, there existed a 
high relative abundance of G to A and C to T mutations (Figure 8A).  Furthermore, the 
relative levels of G to A and C to T mutations varied both between homologues and 
within a given host species. In RhERV2 sequences, half of all nucleotide differences 
found in the CA-NTDs were G to A mutations.  On the other hand, G to A mutations in 
CERV1, CERV2, RhERV1a, and RhERV1b CA-NTDs occurred at frequencies that were 
similar to C to T mutations and both were present at a lower level than all other mutations 
pooled together.  Also in contrast to the mutations in RhERV2 CA-NTDs were those 
found in enMLV CA-NTDs, in which the majority were from neither G to A nor C to T 
substitutions. 
 The most common nucleotide mutations found in mammalian genomes are 
generally G to A and C to T transitions, which are typically caused by spontaneous 
deamination (described below).  APOBEC3-induced deamination of viral reverse 
transcripts can be distinguished from spontaneous deamination of the host genome by the 
existence of certain biases in the dinucleotide context of the mutations.  Namely, 
APOBEC3G specifically deaminates CC dinucleotides on the cDNA minus strand to CU, 
whereas primate APOBEC3F, 3B, and 3H and murine APOBEC3 all mutate TC to TU 
(153-155, 160, 170, 171).  These changes, made during reverse transcription, manifest in 
the positive strand sequence as GG to AG or GA to AA mutations.  Additionally, rare 
deamination of cytidine residues on HIV-1 RNA by APOBEC1 has been reported (194).   
 
 56 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Analysis of ancient ERV CA-NTDs. A) The mean number of G to A, C to T, 
and all other changes (pooled) per CA NTD sequence, relative to each consensus 
sequence is shown. B) The numbers of G to A mutations for each individual CA-NTD 
recovered from sequence databases is plotted as a bar graph (one bar for each provirus) 
and color-coded according to dinucleotide context (i.e. the nucleotide in the +1 position 
relative to the G to A change; red = GG to AG, cyan = GA to AA, green = GC to AC, 
magenta = GT to AT).  The CA NTD sequences are arranged from left to right in order of 
increasing numbers of total G to A changes. C) The mean number of G to A changes per 
CA-NTD sequence, relative to the consensus, is plotted for pooled data for each virus 
species and color coded according to dinucleotide context as in B. C) The percentage of 
G to A changes in each dinucleotide context relative to consensus sequence is plotted, 
and normalized according to the dinucleotide composition of the species-specific 
consensus sequences. The p-values for deviation from a random distribution were 
calculated using the chi-squared test. 
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In order to ask whether the excessive G to A and C to T changes found in the 
endogenous gammaretroviruses were caused by spontaneous deamination of proviruses 
in the host genome or by the catalytic action of antiviral deaminases, the dinucleotide 
context of these mutations was quantified to detect any biases that may have existed.  
Because the number of mutations observed in each individual CA-NTD was rather small, 
we inspected both the pooled CA-NTD sequence data from each viral species (Figure 8C) 
as well as the individual CA-NTD sequences (Figure 8B). There was significant variation 
in the burden of G to A mutations among individual CA-NTDs: while some completely 
lacked G to A mutations, others contained up to 12 G to A mutations in the ~400 
nucleotide CA-NTD encoding sequence (Figure 8B). Moreover, striking and variable 
biases in the patterns of G to A mutations were observed. For example, in CERV1 CA-
NTDs, G to A changes occurred primarily in the context of GG dinucleotides (Figure 8B, 
C). This bias was statistically significant, and was maintained when corrected for the 
frequency with which each GN dinucleotide occurred in the consensus sequence (Figure 
8D). In CERV2 CA-NTDs, the occurrence of G to A changes was biased toward both GG 
and GC dinucleotides; however, in this case the overall numbers of G to A changes were 
small (Figure 8B) because only 10 CERV2 proviruses are present in chimpanzee DNA.  
Interestingly, compared to each of their chimpanzee counterparts, the rhesus macaque 
endogenous gammaretroviruses RhERV1a and RhERV2 exhibited a different mutational 
bias: G to A mutations occurred frequently at both GG and GA dinucleotides, and these 
biases were also highly statistically significant (Figure 8B, C).  In contrast, RhERV1b CA 
NTDs were quite different in that they had relatively few G to A mutations and their 
occurrence was unbiased with respect to dinucleotide context (Figure 8B).  
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Confirmation of mutational biases in endogenous gammaretroviruses 
The sequence analyses above suggested that some endogenous proviruses may 
well have encountered antiviral cytidine deaminases. Therefore, to confirm and extend 
these observations, we asked if similar patterns of mutation could be observed in another 
region of the endogenous proviruses, in particular envelope (Env) sequences (Figure 9). 
Because there are large numbers of CERV-1 proviruses and the chimpanzee genome 
database contained abundant unresolved regions, we retrieved only envelope sequences 
that were linked to CA-NTDs that had either $1 G to A mutations or %4 G to A mutations 
(10 of each).  Overall, there was a good correlation between the CA-NTD and Env 
sequences in terms of the burden of the G to A mutations and the dinucleotide context in 
which they occurred (Figure 10 A, B).  Specifically, the occurrence of GG to AG 
mutations in a given CERV1 CA-NTD strongly predicted the occurrence of the same 
type of mutation in the linked Env sequence, while CA-NTD sequences that contained 
one or no G to A mutations were linked to envelopes that contained relatively few G to A 
mutations that largely lacked a dinucleotide bias.  Indeed, there was only one exception to 
this finding among the 20 CERV-1 sequences analyzed, in which a CA-NTD bearing 
three GG to AG mutations was linked to an Env sequence containing a light and unbiased 
burden of G to A changes (Figure 10 A, B). 
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Figure 9.  Phylogenetic tree illustrating the relationship between endogenous primate 
gammaretroviral Env sequences and other gammaretroviral Envs. A sequence alignment, and 
phylogeny of Env sequences from CERV1, CERV2, RhERV1a, RhERV1b, RhERV2, and 
enMLV and various prototype gammaretroviruses was generated using ClustalX software. The 
tree diagram was generated and edited using FigTree software. 
 
Because there are only ten CERV2 proviruses in the chimpanzee genome (and 
only four of them are complete, with others ranging in size from 2.6 to 7.7 kb) we took a 
different approach to confirm or refute the notion that they contained excessive or biased 
G to A mutations.  Specifically, we analyzed all of the available sequence for all ten 
proviruses. In part because the CERV2 proviruses were intrinsically divergent, and 
differed in length, the absolute numbers of G to A changes as compared to the consensus 
sequence was quite variable among them (Figure 10C).  However, when the character of 
the G to A mutations was examined, five of the 10 proviruses exhibited a clear, 
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statistically significant, excess of GG to AG mutations, as compared to overall G to A 
changes (Fig 10C).  Thus, the patterns of nucleotide substitutions strongly suggested that 
both groups of endogenous gammaretroviruses that integrated into the chimpanzee 
genome in the past few million years frequently encountered the only mutagen known to 
preferentially induce GG to AG mutations, namely APOBEC3G, prior to or during 
endogenization.  
The coverage of the rhesus macaque reference genome database was less 
complete compared to that of the chimpanzee, so only 23, 10 and 22 envelope sequences 
that were unambiguously linked to CA-NTDs could be retrieved for RhERV1a, 
RhERV1b and RhERV2 respectively.  Moreover, in the case of RhERV2, the CA-NTD 
linked env genes were distributed between two distinguishable subgroups and, therefore, 
a separate Env consensus sequence was deduced for each group.  For both RhERV1b and 
RhERV2 the analysis of env sequences corroborated the results obtained using CA-NTDs 
(Fig 10, B).  Specifically, the numbers of G to A changes in RhERV1b Env, like CA-
NTD sequences were modest and unbiased with respect to dinucleotide context; while in 
RhERV2, there was a clear excess of both GG to AG and GA to AA mutations in both 
CA-NTD and Env sequences (Figure 10A, B).  However, while there was concordance 
with respect to overall context bias of G to A mutations present in RERV2 CA-NTD and 
Env sequences, inspection of individual linked CA-NTD and Env sequences revealed that 
the burden and character of G to A mutations was variable.  Specifically, several Env 
sequences bore a large proportion of G to A substitutions in GA dinucleotides while two 
other Env sequences bore predominantly GG to AG hypermutation.  Additionally, the  
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Figure 10. Analysis of G to A changes in CA-NTD and Env sequences in primate 
gammaretroviruses. A and B) CA-NTD sequences from the primate gammaretroviruses 
were selected according to whether an unambiguously linked Env sequence could be 
retrieved from the genome database. In the case of CERV1, ten sequences that essentially 
lacked G to A changes and Ten sequences that had four or more G to A changes were 
selected. For each virus species each sequence is plotted as a bar graph (one bar for each 
provirus) and color-coded according to dinucleotide context (i.e. the nucleotide in the +1 
position relative to each G to A change; red = GG to AG, cyan = GA to AA, green = GC 
to AC, magenta = GT to AT).  The CA NTD sequences are arranged from left to right in 
order of increasing numbers of total G to A changes in CA-NTD sequences (A).  The 
same analysis was performed for the linked env sequences (B), which are arranged in 
order according to the linked CA-NTD sequence.  C) All ten CERV2 proviral sequences 
were analyzed and the dinucleotide context in which G to A mutations occurred is plotted 
and color-coded as in A (left) panel. Additionally, The percentage of G to A changes in 
each dinucleotide context relative to consensus sequence is plotted, and normalized 
according to the dinucleotide composition of the consensus sequences (right panel). The 
p-values for deviation from a random distribution were calculated using the chi-squared 
test. Proviruses 1, 4, 6 and 7 are complete.  
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degree to which CA-NTDs and Env sequences were mutated in individual proviruses did 
not always correlate; in some cases hypermutated RhERV2 Env sequences were linked to 
CA-NTD sequences that bore relatively few G to A changes (Figure 10A, B).  In 
RhERV1a, the nature and burden of G to A changes in Env sequences was not at all 
predicted by the findings in the CA-NTD sequences. Indeed, the preferential occurrence 
of G to A changes in Env in the context of GG and GA dinucleotides was marginal, and 
clearly less pronounced than in the CA-NTD sequences (Fig 10, A, B).  These results, 
and the discordant findings with respect to G to A mutation in a few RhERV2 CA-NTD 
versus linked Env sequences are either explained by variable mutation frequencies across 
genomes (a known characteristic of APOBE3G induced mutation) or by recombination 
between hypermutated and non-hypermutated viral genomes that occurred prior to or 
during deposition in the germ line.  Indeed, inspection of several complete or nearly 
complete RhERV2 proviruses revealed clear variation in the extent of G to A mutation in 
some (but not all) proviruses across the viral genome (Figure 11).  Notably, an obvious 5’ 
to 3’ gradient of increasing mutation intensity was present in some examples bearing 
excessive G to A mutations, as has previously been reported in hypermutated HIV-1 
genomes (171, 172).  Also, several recombination break points were implied by abrupt 
differences in the frequency of APOBEC3-induced mutation.  
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Figure 11.  Examples of the RhERV2 proviruses illustrating variation in type, burden, and 
distribution of G to A mutations among endogenous primate gammaretroviruses. Each horizontal 
line represents a complete or nearly complete ~8.5kB provirus (nucleotide position scale is given 
at the bottom of the diagram), vertical marks indicate the position of G to A mutations relative to 
the RhERV2 consensus sequence and are color coded according to dinucleotide context (i.e. the 
nucleotide in the +1 position relative to each G to A change; red = GG to AG, cyan = GA to AA, 
green = GC to AC, magenta = GT to AT).  Yellow marks indicated non-G to A mutations, 
including in/dels. 
 
Biased patterns of G to A mutation in primate ERVs are not explained by 
spontaneous cytidine deamination 
 The chimpanzee and rhesus gammaretroviral CA-NTD and Env sequences also 
contained a striking excess of plus strand C to T changes relative to their respective 
consensus sequences (Figure 8A).  Potentially, the high rate of C to T mutations in CA-
NTD sequences could be the result of cytidine deamination after integration of the 
provirus into the germ line. Correspondingly, excessive plus strand G to A changes could 
be a reflection of cytidine deamination events on the minus strand within the host 
genome.  In contrast to APOBEC3-mediated deamination events, which occur 
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specifically on the anti-sense DNA strand and are profoundly influenced by the identity 
of the nucleotide in the -1 position relative to the deaminated cytidine, mutations that 
arise as a result of cytidine deamination in the host genome are influenced by the 
nucleotide in the +1 position and lack any strand specificity.  Specifically, the most 
common cytidine deamination-induced mutation found in mammalian genomes occurs in 
the context of CG dinucleotides (i.e. G in the +1 position).  This results in CG to TG or 
CG to CA sense mutations depending on whether CG dinucleotides on the plus or minus 
strand are deaminated, respectively (264, 265).  This phenomenon is explained by a 
transcriptional control mechanism that operates by cytidine methylation of CG islands.  
When genomic 5-methyldeoxycytosine is deaminated, deoxythymidine is formed.  
Therefore, if a CG to TG mutation (or its anti-sense counterpart, CG to CA) is found in 
an endogenous retrovirus it is likely the result of deamination of proviral nucleotides 
during long-term residence in the host genome as opposed to deamination by restriction 
factors during exogenous replication.  Interestingly, it is possible that deamination of CG 
dinucleotides in the cellular genome is catalyzed by the APOBEC family member, 
activation-induced cytidine deaminase (AID).  This is suggested by the observation that 
AID expression is required for proper demethylation in pluripotent stem cells (266, 267).  
It was proposed that during reprogramming of gene expression, silenced DNA can be 
demethylated through the deamination of methyl-cytidine followed by T:G base excision 
repair by glycosylases.  If this mechanism resulted in mutations of endogenous 
retroviruses, though, it would be due to their presence in the cellular genome rather than 
the result of a specific antiviral activity.   
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 To account for the potential “noise” introduced by deamination in the cellular 
genome, we counted and categorized all G to A and C to T changes for both CA-NTD 
and Env sequences before and after exclusion of CG dinucleotides (Figure 12).  Notably, 
in an analysis of plus strand C to T mutations there were no evident biases in the -1 
position after the exclusion of substitutions that occurred in CG dinucleotides (Figure 
12C, D).  This confirms that the APOBEC3 activities identified had minus-strand 
specificity.  Moreover, exclusion of C to T mutations that occurred in the context of CG 
dinucleotides on the minus strand, reduced the overall number of plus strand G to A 
mutations but did not affect conclusions with respect to their associated dinucleotide 
context biases (Figure 12A, B).  
 Notably, the relative extent of G to A as compared to C to T mutations varied 
among individual proviruses of a given virus group as well as between virus groups.  This 
was most evident in the analysis of Env sequences (or complete proviral sequences in the 
case of CERV2), because the longer length of sequence analyzed permitted a more robust 
estimate of G to A and C to T mutation frequencies (Figures 13, 14).  For many of the 
individual CERV1, CERV2, and RhERV2 proviruses, the frequency of G to A mutations 
greatly exceeded the frequency of C to T mutations (Figure 13A, C, Figure 14), and in 
proviruses where this was the case, the excessive G to A mutation was invariably in the 
context of GG or GA dinucleotides, and remained evident when CG dinucleotides were 
purged from the analysis (Figure 13B, D and Figure 14). Conversely, RhERV1a and 
RhERV1b Env sequences exhibited broadly similar levels of comparatively unbiased G 
to A and C to T mutation (Figure 13) suggesting that the frequency of APOBEC3-
induced mutation was low compared to that from other sources. A comparison with  
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Figure 12. Comparative analysis of the context in which G to A versus C to T changes 
occur in primate gammaretroviral CA-NTDs. (A) Each sequence is plotted as a bar graph 
(one bar for each provirus) and color-coded according to dinucleotide context (i.e. the 
nucleotide in the +1 position relative to each G to A change; red = GG to AG, Cyan = 
GA to AA, Green = GC to AC, magenta = GT to AT) the CA NTD sequences are 
arranged from left to right in order of increasing numbers of total G to A changes in CA-
NTD sequences (panel A contains the same data as Figure 10A) (B) Same analysis as in 
A, except mutations were enumerated after removal of minus strand CG to TG (plus 
strand CG to CA) mutations. (C) Analysis of plus strand C to T mutations, in the same 
CA-NTD sequences, in the same order, (left to right) as in A and B.  C to T changes are 
color-coded according to the nucleotide in the -1 position relative to each C to T change; 
red = CC to CT, Cyan = TC to TT, Green = GC to GT, magenta = AC to AT) (D) Same 
analysis as in C, except mutations were enumerated after removal of plus strand CG to 
TG mutations. 
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endogenous MLVs revealed a similar situation to that in primate gammaretroviruses, and 
as was previously reported, two out of the three groups of endogenous MLVs (Pmv, 
Mpv, but not Xmv) exhibited higher levels of G to A than C to T mutations, and this 
excess in G to A mutations was associated with similar context biases (268). Overall, 
clear dinucleotide context biases were observed in each situation where G to A mutations 
clearly outnumbered C to T mutations. 
 Thus, the excessive and context-biased G to A mutations that are present in some 
of the groups of primate endogenous gammaretroviruses cannot be explained by 
spontaneous cytidine deamination. Rather, the analysis of both CA-NTD sequences, and 
linked envelope sequences, provides robust support for the hypothesis that APOBEC3G 
in chimpanzees, and a combination of APOBEC3G and other APOBEC3 proteins in 
rhesus macaques, extensively mutated ancient gammaretroviral genomes prior to and/or 
during their endogenization.  If endogenization involved multiple rounds of replication in 
reproductive organs, then the high expression levels of APOBEC3 proteins in the ovaries 
and testes suggest that they may have been able to act on viruses during endogenization 
(269).   
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Figure 13. Comparative analysis of the burden of, and the context in which, G to A 
versus C to T changes occur in endogenous primate and murine gammaretroviral Env 
sequences. (A) Each sequence is plotted as a bar graph (one bar for each provirus) and 
color-coded according to dinucleotide context as before. The primate Env sequences are 
derived from the same proviruses as the CA-NTD sequences shown in Figure 12, and 
arranged from left to right in the same order (panel A contains the same data as Figure 
10B) (B) Same analysis as in A, except mutations were enumerated after removal of 
minus strand CG to TG (plus strand CG to CA) mutations. (C) Analysis of plus strand C 
to T mutations, in the same Env sequences, in the same order, (left to right) as in A and 
B.  C to T changes are color-coded according to the nucleotide in the -1 position relative 
to each C to T change as before. (D) Same analysis as in C, except mutations were 
enumerated after removal of plus-strand CG to TG mutations. 
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Figure 14. Comparative analysis of the burden of, and the context in which, G to A versus C to T 
changes occured in CERV2 proviruses. (A) Each sequence is plotted as a bar graph (one bar for 
each provirus) and color-coded according to the dinucleotide context in which G to A mutations 
occur, as described above. The proviral sequences correspond to the CA-NTD sequences shown 
in Figure 12, and arranged from left to right in the same order. The left panel shows analysis 
without removal of minus strand CG dinucleotides, while the right panel shows analysis after 
their removal. (B) Analysis of plus strand C to T mutations, in the same CERV2 proviral 
sequences, in the same order, (left to right).  C to T changes are color-coded according to the 
nucleotide in the -1 position relative to each C to T change as is Figure 12. The left panel shows 
analysis without removal of plus strand CG dinucleotides, while the right panel shows analysis 
after their removal. 
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Effects of cytidine deamination on ancient primate gammaretrovirus CA-NTD 
function 
 Inspection of the endogenous primate gammaretroviral CA-NTD sequences 
revealed that, with the exception of RhERV1b CA-NTD sequences, many harbored stop 
codons (Figure 15A). Strikingly, G to A mutations generated a large fraction of the stop 
codons. C to T changes resulted in stop codons somewhat less frequently than G to A 
changes, but still provided a major source of these obviously inactivating mutations.  
Frameshifts and other mutations were responsible for only a small proportion of protein 
truncating mutations. Many of the C to T changes occurred in CG dinucleotides and are 
therefore likely to be caused by spontaneous post-integration deamination events. 
Notably, all of the stop codons that arose through the appearance of G to A mutations 
were due to a change from Trp (TGG) to termination codons (TAG, TGA or TAA), often 
reflecting the dinucleotide bias associated with the G to A changes observed in those 
species. The large number of stop codons generated at Trp codons, likely by APOBEC3-
mediated cytidine deamination, would almost certainly functionally inactivate many of 
these ancient endogenous retroviruses. Note that this analysis was confined to the CA-
NTD sequences, and thus indicates the predominate source of termination codons, but 
significantly underestimates the total number of termination codons in full-length 
proviruses. 
 In addition to stop codons, G to A and C to T changes introduced missense 
mutations in CA NTDs whose effects cannot be determined simply by inspecting 
sequence data. Although it was not practical to determine the effect of each G to A and C 
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to T mutation in isolation, a few (fourteen) members of the libraries of chimeric CERV1- 
RhERV1a- or RhERV1b-MLVs bore single, naturally occurring, missense mutations that 
could likely be attributed to enzymatic cytidine deamination (GG to AG changes) or 
spontaneous cytidine deamination (CG to CA or CG to TG changes).  Chimeric MLVs 
bearing these single mutations were invariably less infectious than corresponding MLVs 
encoding the intact CERV1, RhERV1a or RhERV1b consensus CA-NTD sequence 
(Figure 15B). The magnitudes of the decreases in infectivity were variable, and in one 
case a missense GG to AG mutation completely inactivated a CERV1-MLV chimera. 
Thus, amino acid differences from the consensus, likely attributable to enzymatic or 
spontaneous cytidine deamination decreased infectivity, suggesting that they were 
unlikely to be positively selected to provide benefit to a replicating virus. Rather, in 
addition to their propensity to induce the occurrence of termination codons, the abundant 
nonsynonymous G to A and C to T changes likely contributed significantly to a 
deleterious genetic load borne by these populations of endogenized viruses. 
 76 
 
 
 
Figure 15. Effects of cytidine deamination on CA-NTD function. A) the percentage of translation 
termination codons generated by G to A, C to T, frameshift and other mutations in endogenous 
primate and mouse gammaretroviral CA-NTDs. The percentage of all CA-NTD sequences with 
stop codons in CERV1, CERV2, RhERV1a, RhERV1b, RhERV2, and enMLV CA-NTDs is 
plotted and the colored subdivision indicate the proportions that are attributable to each type of 
mutation. B) Effect of single G to A and C to T missense mutations on the infectivity of chimeric 
MLVs bearing CA-NTDs from primate endogenous retroviruses.  Consensus capsid NTDs from 
the indicated virus species and variants bearing single naturally occurring G to A mutations (red) 
or C to T mutations (cyan) were introduced into chimeric MLV GagPol and infectivity measured 
as in Figure 7.  Note that all three G to A mutations in CERV1 (#46, #23, #34) occurred in the 
context of GG dinucleotides, while the mutations in RhERV1a and RhERV2 were all in the 
context of CG dinucleotides on the plus strand (blue) or minus strand (red). 
 
CERV2 restriction by APOBEC3 proteins in vitro 
 It is clear from the analyses presented above that APOBEC3G was capable of 
heavily mutating CERV2, but this alone does not necessarily indicate that APOBEC3G 
was able to broadly restrict its replication.  Indeed, APOBEC3G is able to induce 
mutations in HERV-K without restricting a HERV-K consensus during a single cycle of 
replication (13, 270).  Also, in spite of the ability of HIV-1 to avoid restriction by human 
APOBEC3 proteins through the action of Vif, hypermutated proviruses are abundant in 
 77 
infected patients (192, 193, 197, 271).  Furthermore, HIV-1 can accumulate APOBEC3-
associated mutations in cells that allow equal replication of Vif-deficient and Vif-
proficient viruses (Chapter IV).  These results point out that APOBEC3-induced mutation 
is observable even when viruses are not susceptible to its restrictive effects.  Thus, it 
becomes necessary to confirm, in vitro, that APOBEC3G is capable of restricting CERV2 
infection.   
 It has been posited that the incorporation of APOBEC3G into HIV particles 
occurs through its interaction with virion-packaged RNA and nucleocapsid (162-168).  
Even in the absence of viral RNA, though, APOBEC3G was shown to both incorporate 
into virions and interact with Gag in an RNA- and nucleocapsid-dependent manner (162, 
164, 165, 168).  This suggested that APOBEC3 packaging depends, not on specific 
sequences in the viral genomic RNA, but on nucleocapsid and, in particular, its ability to 
bind RNA.  Further importance of nucleocapsid in APOBEC packaging has been shown 
for human T cell leukemia virus type 1, which contains a peptide motif at the C-terminus 
of nucleocapsid that is unique to primate T cell leukemia viruses and is responsible for 
the exclusion of APOBEC3G from particles (272).  Overall, it is clear that the inclusion 
of the major structural components of CERV2 is warranted in an in vitro study of CERV2 
restriction by APOBEC3.  Thus, we constructed a consensus CERV2 Gag gene and 
combined it with MLV Pol to make a chimeric GagPol (CERV2Gag-MLVPol).  Due to 
the requirement for MLV protease to process the CERV2 Gag in the maturation of 
chimeric particles, a second version of CERV2 Gag (CERV2/MLV Gag) was synthesized 
that replaced four amino residues on both sides of protease cleavage sites with those from 
MLV (Figure 16A).  Both chimeric GagPol proteins were functional in the context of 
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VSV enveloped virions carrying a GFP reporter and, interestingly, intact CERV2 Gag 
protease cleavage sites yielded particles with a titer that was two orders of magnitude 
higher than particles containing cleavage sites from MLV Gag (Figure 16B).   
 To measure restriction by APOBEC3G, variable amounts of Myc-tagged human 
APOBEC3G were co-transfected with VSVg, an MLV vector encoding a GFP reporter, 
and either MLV GagPol or CERV2Gag-MLVPol.  APOBEC3G was able to restrict 
virions containing CERV2 Gag by up to approximately one order of magnitude, which 
was similar to the restriction of particles carrying MLV Gag (Figure 16C).  This result 
suggests that APOBEC3G was, indeed, capable of restricting CERV2 replication.  To 
address a possible role for APOBEC3G in preventing CERV2 endogenization in the 
human lineage, it was determined if human APOBEC3G was potentially more potent 
against CERV2 than orthologues from species whose genomes were invaded by CERV2 
family members.  VSV-G enveloped CERV2Gag-MLVPol, MLV GagPol, or HIV 
GagPol virions were generated in the presence of variable amounts of APOBEC3G from 
human, chimpanzee, or rhesus macaque (Figure 17).  Although human APOBEC3G was 
more potent in terms of its restrictive effects compared to rhesus macaque APOBEC3G, 
it was weaker than chimpanzee APOBEC3G.  Furthermore, this order of APOBEC3G 
potency was observed in the restriction of all three viruses tested.  Therefore, a protection 
of the human lineage from CERV2 cannot be ascribed to a restriction by APOBEC3G 
that was potentially more powerful in human ancestors than it was in primates that were 
unable to avoid CERV2 endogenization. 
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Figure 16.  A functional CERV2 Gag consensus and its sensitivity to human 
APOBEC3G.  A) Alignment of Gag amino acid sequences:  CERV2 majority consensus 
sequence, CERV2 majority consensus sequence with protease cleavage sites (marked 
with vertical line) matching moloney MLV (CERV2/MLVGag), and moloney MLV.  B) 
VSV enveloped pseudotypes were generated by cotransfection with CNCG and MLV 
GagPol or chimeras containing CERV2 Gag.  The number of infectious units per mL 
supernatant was measured by infection of 10
4
 MDTF with a five-fold serial dilution.  C) 
MLV GagPol or CERV2Gag-MLVPol particles used to infect MDTF were prepared as 
in (B) except with cotransfection of variable amounts of human APOBEC3G expression 
plasmid.  Empty vector was used to maintain the same amount of total transfected DNA.  
The volumes used for infections were chosen to yield MOI 0.3 with APOBEC3G-minus 
virus.  The Gag carried of each virus is indicated.   
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 Although CERV2 hypermutation only occurred in a dinucleotide context that was 
indicative of APOBEC3G activity (i.e. GG), RhERV2 hypermutation also occurred in a 
dinucleotide context that is targeted by several other APOBEC3 proteins (i.e. GA).  
Therefore, we asked if human APOBEC proteins other than APOBEC3G are capable of 
potently and specifically restricting CERV2, which would suggest that they could have 
protected human ancestors from infection by CERV2.  Restriction of CERV2 Gag virions 
by most APOBEC proteins tested, though, was non-existent compared to APOBEC3G 
(Figure 18).  It should be noted that editing of ApoB mRNA by APOBEC1 involves the 
APOBEC1 complementation factor (ACF) (273, 274) and perhaps inclusion of ACF 
could alter the results presented here.  In contrast to the lack of activity observed in most 
APOBEC proteins tested, human APOBEC3F and APOBEC3A were able to moderately 
restrict CERV2 infection (two- and three-fold, respectively) but none of the restriction 
activities observed showed specificity for CERV2Gag virions over those containing 
MLV Gag.  Although the data presented here indicate that APOBEC3 proteins were 
likely able to restrict CERV2 replication, there is no direct evidence that these restrictions 
were responsible for protecting the human lineage from CERV2 infection. 
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Figure 17. Restriction of CERV2 Gag-containing virions by human, chimpanzee, or rhesus 
macaque APOBEC3G.  A) Titration of APOBEC3G was done as described in Figure 16C except 
myc-tagged APOBEC3G genes from three different species were used as indicated.  Additionally, 
HIV virions were generated by cotransfection of VSVg, NL GagPol, and CSGW.  B) Following 
harvesting of the supernatent used for infections in (A), 293T cells transfected with MLV GagPol 
were lysed in SDS-PAGE loading buffer for western blots probed with rabbit anti-MLV capsid or 
mouse anti-Myc antibodies to the detect the 46kDa APOBEC3G proteins. 
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Figure 18.  Lack of potent restriction of CERV2Gag-MLVPol by human APOBEC proteins other 
than APOBEC3G. A) The indicated human APOBECs were titrated as in Figure 17, except a 
maximum of 600ng (rather than 300ng) APOBEC expression plasmid was used. B) Lysates from 
MLV virus-producing cells used in (A) were used for western blot with a rabbit anti-MLV capsid 
antibody. 
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Chapter IV. The impact of APOBEC3 proteins on HIV-1 evolution in vitro 
 
 
 HIV-1 was used to investigate the potential impact of APOBEC3-induced 
mutation on a replicating viral population.  The interaction between HIV-1 and 
APOBEC3 proteins is complex.  Although its Vif protein protects HIV-1 from restriction 
by human APOBEC3 proteins, hypermutated proviruses are abundant in infected patients 
(192, 193, 197).  It is currently unclear if these variants impose a significant burden to 
overall fitness of the viral population, thus constituting a deleterious genetic load.  
Another possibility, and one that is quite the opposite of the first, is that they can 
contribute an increase in variability that could benefit a rapidly evolving population, 
perhaps through recombination with fit viruses.  Or, perhaps hypermutated proviruses 
neither positively nor negatively affect HIV-1 evolution due to debilitating mutational 
scars that have left their gene products entirely inactive and their genomes too 
unrecognizable to even be packaged by competent viruses.  To explore these possibilities, 
we observed the accumulation of APOBEC3-induced diversity during HIV-1 replication 
in vitro and the resulting viral populations were tested for their ability to evolve under 
selective pressures. 
 
Replication of HIV-1 delta Vif in permissive and semi-permissive cell lines 
 In order to assess the impact that APOBEC3-induced mutation has on a 
replicating viral population in terms of both its overall fitness and adaptive potential, 
HIV-1 or an HIV-1 lacking Vif expression (#Vif) were allowed to replicate in human T-
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cell lines.  Both viruses expressed GFP in place of NEF (to track the spread of virus 
through the culture) and also contained mutations that prevented Vpr expression.  The 
latter was used to preempt a loss of Vpr that can occur during long-term culture and can 
enhance virus replication (275).  Two different cell lines, MT2 and CEMSS, both allowed 
replication of #Vif virus but the Vif phenotype displayed in the two cell lines differed 
(Figure 19).  The replicative fitness of #Vif in CEMSS cells, as predicted by the 
literature, was identical to that of the virus carrying intact Vif (Vif+) (152, 160).  The 
genetic screen that identified APOBEC3G as a host factor antagonized by Vif made use 
of this permissive phenotype of CEMSS (152).  Replication of #Vif in MT2 cells, on the 
other hand, was restricted relative to Vif+ but not but not enough to prevent a spreading 
infection that overtook the culture within five days- a two-day delay compared to Vif+.  
A Partial restriction of #Vif replication has also been observed in activated PBMC and, 
therefore, the #Vif phenotype observed in MT2 cells may be more realistic than that 
displayed in restrictive cell lines that entirely extinguish #Vif replication (211). 
 The cytopathicity of the #Vif and Vif+ viruses also differed.  To maintain the 
MT2 culture infected with Vif+ (MT2/Vif+), fresh cells were added every three days 
beginning four days post-infection to counteract frequent cell death (the ratio of fresh to 
infected cells was approximately 1:4).  In contrast, maintenance by the addition of 
healthy cells was not necessary in MT2/#Vif cultures where cell death was rarely 
observed.  The relative robustness of MT2 cells infected with #Vif may be due to a lower 
level of infectious virus in the culture.  A titration of cell culture supernatant collected 15 
days post-infection (dpi) was carried out by infecting MT2 cells overnight before the  
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Figure 19.  Replication of HIV with or without Vif in MT2 or CEMSS cells.  A) 10
6 
MT2 or 
CEMSS cells were infected at MOI 0.001 with HIV-1 NL4.3/HxB/GFP delta Vpr with Vif (Vif+) 
or deficient in Vif (#Vif).  Aliquots of cells were fixed periodically for detection of GFP-positive 
cells by FACs analysis.  <0.1% GFP-positive (or <5 cells) is considered background based on 
measurements of un-infected cells.  B) Supernatants were collected from cultures described in (A) 
at 15 dpi and titrated on 10
4
 MT2 cells.  Infections proceeded overnight before addition of 
dextran sulfate, followed by fixation at two days post-infection.  Infectious titer was derived from 
the percentage of cells positive for GFP. 
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addition of dextran sulfate to prevent multiple replication cycles. The titer of infectious 
virus in supernatent from MT2/#Vif was 20-fold lower than that of MT2/Vif+ at 15 dpi 
(Figure 19B).  It should be noted that these infections included restriction by any 
APOBEC3 proteins that may have been packaged into virions from the previous culture. 
 The behavior of infected CEMSS was different from that observed in infected 
MT2.  The infected CEMSS displayed frequent syncytia rather than cell death and these 
effects were similar between CEMSS cultures infected with either Vif+ or #Vif.  To 
prevent fusions from occurring in the vast majority of cells, fresh CEMSS were 
periodically added in equal amounts to both of the infected cultures.  Still, after ten days 
of replication, the CEMSS culture infected with Vif+ had a lower percentage of cells that 
were GFP-positive compared to CEMSS infected with #Vif, which may have been a 
reflection of weak GFP expression in unhealthy cells (Figure 19A).  There was no 
apparent difference, though, in the infectious titer of the supernatent in each culture at 15 
dpi (Figure 19B).  These results suggest that Vif may be toxic to the cells and could 
contribute to the cytopathic effect of HIV replication in some cell types.      
 Replication of HIV-1 with or without Vif in restrictive cells presumably resulted 
in viral populations that differed greatly in their sequence diversity due to APOBEC3-
induced mutation.  It remained possible, though, that #Vif was able to replicate 
efficiently in MT2 cells because of a weak penetration of APOBEC3 activity that allowed 
the predominance of individual viruses entirely untouched by deamination over a 
minority population of severely hypermutated viruses.  To determine if APOBEC3-
induced sequence diversity could be observed following a period of continual viral 
replication, #Vif or Vif+ were allowed to replicate in MT2 or CEMSS cells for 15 days 
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before cells and supernatent were collected.  Genomic DNA was purified from cells and 
RNA was extracted from pelleted virions for cDNA synthesis.  A 720-nucleotide locus 
covering the polymerase domain of reverse transcriptase was amplified from both 
proviral DNA in cellular genomes as well as cDNA made from virion-packaged viral 
RNA.  The resulting PCR products were cloned and twelve clones from each were 
sequenced and compared to the wildtype sequence (Figure 20).   All twelve proviral 
sequences from MT2/#Vif contained varying degrees of mutations that were likely 
caused by APOBEC3-catalyzed deamination (Figure 20A).  These G to A substitutions in 
GG or GA dinucleotide contexts varied in quantity from six to 38 per amplicon.  
Surprisingly, APOBEC3-associated mutations were also detected in #Vif proviral DNA 
from non-restrictive CEMSS cells, albeit at levels that were much lower than those 
observed in #Vif proviral sequences amplified from MT2 cells (25 mutations in one 
CEMSS/#Vif sequence and 1-12 mutations in six other clones out of 12 examined).  This 
suggests that levels of APOBEC3 proteins are present in CEMSS cells that are able to 
accomplish a degree of catalytic deamination but are not sufficient to restrict virus 
replication.  In contrast, only a single G to A mutation within a GA or GG context was 
found in proviral sequences from the MT2/Vif+ culture and none were found in 
sequences from CEMSS/Vif+.  In general, other types of mutations were found in a 
minority of the sequences analyzed at a maximum of only one substitution per sequence.    
 An analysis of virion-packaged sequences revealed a different degree of GG to 
AG and GA to AA mutations compared to those observed in proviruses (Figure 20B).  
Although APOBEC3-induced mutations were observed again in the MT2/#Vif culture, 
they were not found in every sequence (8/12) and, where present, there were only 2-10 
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mutations per sequence.  A decreased degree of hypermutation in packaged viral RNA 
relative to integrated provirus may represent a purification of sequences that are either 
not mutated or only moderately mutated by APOBEC3.  Such selection could be 
explained if severe hypermutation resulted in impaired LTR promoter function, the 
degradation of RNAs that contain frequent stop codons by the nonsense-mediated decay 
pathway, or the crippling of the RNA structures responsible for packaging into virions by 
nucleocapsid.  Interestingly, there were three virion sequences from MT2 cultures 
infected with Vif+ virus and two from CEMSS infected with #Vif virus that contained a 
small number of APOBEC3-associated mutations (1-3 mutations/sequence).  In spite of 
the small sample size of sequences in these analyses, it is clear that the population of 
#Vif viruses in MT2 cells contained APOBEC3-driven diversity that was represented at 
the level of viral genomic RNA.  This suggests that an encounter of a viral genome with 
APOBEC3 is not necessarily a dead end but, rather, hypermutated sequence may be 
carried by virions during subsequent rounds of replication.  Furthermore, it cannot be 
concluded that either Vif+ virus replicating in #Vif-restricting cells or #Vif virus in non-
restrictive cells are entirely devoid of APOBEC3-induced mutation.  The experiments 
described below explored whether this varying degree of diversity can provide a benefit 
or a burden to evolving viral populations. 
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Figure 20.  Detection of APOBEC3-induced mutations.  A and B) DNA encoding the polymerase 
domain of HIV reverse transcriptase was amplified, cloned, and sequenced.  The number of 
nucleotide substitutions relative to the wildtype sequence is shown for each sequence.  Putative 
APOBEC3-induced mutations are indicated as G to A changes that immediately proceeded a G or 
A residue (blue or red, respectively) and all other nucleotide substitutions were pooled (grey).  
Sequences were divided according to the inoculating virus (Vif+ or #Vif) and the cells in which it 
replicated (MT2 or CEMSS).  Templates for PCR were either cellular DNA preparations (A) or 
cDNA derived from pelleted virions (B).   
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Selection of drug resistance in Vif+ virus  
 We wished to determine if the potential for HIV-1 to acquire drug resistance 
differed according to the degree of APOBEC3-driven diversity.  First, #Vif or Vif+ 
viruses that had been grown in the absence of selection in MT2 cells (MT2/#Vif and 
MT2/Vif+ viruses) were used to infect fresh MT2 cells at MOI 0.001.  AZT, nevirapine, 
or a combination of the two was added to the infected cultures on the following day 
(Figure 22).  The drugs were chosen because they are known to induce the emergence of 
mutations that could potentially be caused by APOBEC3 activity (Table 1).  AZT and 
nevirapine were further selected because they offered a range of concentrations in which 
virus spread in MT2 cells was inhibited but not entirely extinguished (Figure 21).  In 
contrast, inhibition with nelfinavir jumped from slight delays in viral spread to a 
complete inhibition with only a two-fold change in drug concentration; while high 
concentrations of 3TC, at best, caused a two-day delay in the complete spread of virus 
through the culture.   
 
Table 1.  Drug resistance mutations that could result from APOBEC3 
activity 
Nevirapine  AZT  3TC  Nelfinavir 
G190E 
G196E 
M230I 
 
D67N 
R211K 
 
M41I  
M184I  
R211K 
 
D30N 
M46I 
R57K 
G73S 
The amino acid substitutions listed are associated with resistance to the 
indicated drug  and are induced by GG to GA or GA to AA nucleotide 
mutations.  The NL4.3 GagPol sequence was used to determine the 
dinucleotide context of the mutations.  Based on data compiled in the Los 
Alamos National Laboratory and Stanford University HIV Drug Resistance 
Databases and other cited references (211, 276-294). 
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 Figure 21.  Inhibition of spreading infection in MT2 cells by antiretroviral drugs.  106 MT2 cells 
were infected overnight with Vif+ and then split into media containing nevirapine (A), AZT (B), 
3TC (C), or nelfinavir (D) at the indicated concentrations.  Cells were allowed to grow on 24-well 
plates with a 1:5 passage into media containing fresh drug every four days.  100µL of cells were 
fixed at several time-points for quantitation of GFP-expressing (or infected) cells.   
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 The Vif+ virus overtook the MT2 culture within 10 days in the presence of AZT 
and it was also able to rapidly spread through a nevirapine-containing culture after an 
initial decline in the number of infected cells (Figure 22A, B).  Additionally, it took 
MT2/Vif+ about a month to emerge under suppression with a combination of both drugs 
(Figure 22C).  In contrast, MT2/#Vif was not able to overcome any of these three 
challenges.  A titration of nevirapine or AZT in TZM cells during infection with the 
putative drug-resistant viruses revealed that nevirapine resistance had, indeed, been 
acquired by MT2/Vif+ during both single and dual-drug selections; but neither AZT 
alone nor AZT in combination with nevirapine had induced any drug resistance (Figure 
23).  Inhibition with AZT at the chosen concentration was apparently only sufficient to 
delay the rapid spread of Vif+, while nevirapine was potent enough to elicit the 
emergence of drug resistance mutation(s).  Amplification, cloning, and sequencing of 
reverse transcriptase polymerase domain sequences from proviruses at the end of 
selection with nevirapine revealed a variety of mutations associated with nevirapine 
resistance in 8/10 sequences (Figure 24).  One of these amino acid substitutions, M230I, 
was the result of a GG to AG mutation.  M230I was found in two sequences: one only 
contained a single point mutation and the other contained 24 other APOBEC3-induced 
amino acid mutations, including three stop codons.  The hypermutant also contained 
another predicted nevirapine resistance mutation, Y188C, which was not caused by a G 
to A substitution and was shared by three other sequences.  It is possible that during the 
course of its escape, this individual accumulated one or both beneficial mutations before 
a detrimental hypermutation by APOBEC3.   
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 The lack of drug resistance evolution in #Vif virus could be due to a continual 
restriction by APOBEC3 proteins in MT2 cells during selection rather than a deleterious 
effect of pre-existing genetic loads.  Perhaps restriction, although not enough to prevent 
the spread of #Vif through a culture that lacked drugs, severely decreased the odds of an 
emergence by rare escape mutants.  To address this, selection with nevirapine was 
repeated using CEMSS cells where a lack of Vif did not result in lower replication 
kinetics.  In this experiment, viruses that were grown for 15 days without selection in 
MT2 cells (termed MT2/Vif+ and MT2/#Vif viruses) as well as viruses grown in 
CEMSS cells (termed CEMSS/Vif+ and CEMSS/#Vif viruses) were used to infect fresh 
CEMSS at an equivalent MOI of 0.001.  Nevirapine was added three days after infection 
at a concentration that was capable of inhibiting a spreading infection in CEMSS cells 
(Figure 25A).  It should be noted that even in the absence of drug, MT2/#Vif displayed a 
slower replication kinetic than the other three viruses- perhaps the effect of a deleterious 
load of mutations (Figure 25B).  Three weeks after infection, only CEMSS/Vif+ was able 
to overcome inhibition by nevirapine; which, out of the four populations used to initiate 
the selection, was the most likely to be devoid of any APOBEC3-induced mutations.  
Therefore, these experiments demonstrate that immense diversity generated by 
APOBEC3 in the absence of Vif does not necessarily make a productive contribution to 
drug resistance evolution.  It is possible that such potential can be outweighed by an 
associated genetic load.  Nevertheless, the occurrence of M230I in MT2/Vif+ following 
selection with nevirapine, suggests that it is possible for low levels of APOBEC3-induced 
mutation in Vif-positive viruses to productively contribute to evolution.  It is worth 
noting that in order to attain a low MOI before selection began, a bottleneck was imposed 
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on the viral population and it is possible that this resulted in the loss of some potentially 
beneficial APOBEC3-induced mutations.  Perhaps the use of larger initial population 
sizes prior to selection could allow the inclusion of broader diversity and, thus, reveal 
greater evolutionary potentials. 
 
Figure 22.  Single and dual-drug selection in MT2 cells.  Vif+ or #Vif viruses were grown in 
MT2 cells for 15 days (Figure 19), and then used to infect fresh MT2 at MOI 0.01.  One day after 
infection, cells were split into plain media, 4µM nevirapine (A), 4µM AZT (B), or a combination 
of 4µMAZT and 0.5µM nevirapine.  Growth curves are plotted as percent infected cells 
(expressing GFP) verses days post-infection. 
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Figure 23.  Evolution of nevirapine but not AZT resistance.  TZM cells were infected at MOI 0.3 
in media containing increasing concentrations of AZT (A and C) or nevirapine (B and D).  Cells 
were infected with either the Vif+ virus used to initiate selection experiments or resultant Vif+ 
viruses after spread through MT2 cells in the presence of the indicated drug (A and B) or drugs 
(C and D).  TZM infection was quantified two d.p.i. in relative luminescence units by a luciferase 
activity assay.  Inhibition relative to a minus-drug control (%) is plotted verses drug 
concentration.   
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Figure 24.  Nevirapine resistance mutations.  Following selection with 4µM nevirapine, 
proviral sequences encoding the reverse transcriptase polymerase domain were amplified 
from MT2 cellular DNA, cloned and sequenced.  An alignment of the amino acid 
sequence from 10 clones and the wildtype NL4.3 sequence is shown.  Primer-binding 
sites, including the first six codons of reverse transcriptase, were excluded.  Sequences 
with common mutations were ordered together.  Amino acid changes predicted to confer 
a decrease in sensitivity to nevirapine are marked with boxes (286, 287, 290, 291, 293, 
294) and one of these (marked in blue) was caused by a G to A mutation in a GG 
dinucleotide context. 
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Figure 25.  Selection with Nevirapine in CEMSS cells.  A) Titration of nevirapine in infected 
CEMSS was done as described in Figure 21 for drug titrations in MT2 cells.  B and C) Vif+ or 
#Vif grown 15 days in MT2 or CEMSS cells were used to infect CEMSS cells at MOI 0.001.  
Three days later, cells were split into plain media (B) or media containing 500nM nevirapine (C).     
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Selection of an escape mutant using patient plasma with neutralizing activity 
 In addition to in vitro drug-resistance evolution experiments, we also attempted to 
evolve escape mutants under selection by antibodies present in broadly neutralizing sera.  
Aside from providing a further examination of the evolutionary potential of APOBEC3-
mutated viruses, this type of selection experiment could also potentially identify novel 
antigens targeted by neutralizing antibodies or more general determinants of 
neutralization sensitivity.  Selective pressure was imposed by blood plasma containing 
broadly neutralizing activity that was taken from an HIV-1 infected, untreated individual 
with long-term low levels of viremia (i.e. a long-term non-progressor) (295).  For this 
experiment, Vif+ virus was grown in MT2 cells and, therefore, only trace levels of 
APOBEC3-induced mutations were expected.  One day after infection at MOI 0.001, 
MT2 cells were split into varying dilutions of neutralizing plasma.  Every four days, 
cultures were split 1:5 into media containing fresh plasma.  A 1:20 dilution of the plasma 
was initially able to prevent detectable virus replication for one week.  Then, a steady 
spreading infection was apparent over an additional one-week period before a plateau 
persisted with 3-4% of the cells infected (Figure 26A).  The resulting virus was titrated 
and used in a second round of selection alongside the original virus stock (Figure 26B).  
In spite of a slight fitness disadvantage, the selected virus was far less susceptible to 
neutralization than its un-selected counterpart and after approximately two weeks of 
additional selection, cells and supernatent were harvested for further analysis.   
 A titration of the patient plasma in a single-cycle infection demonstrated that two 
rounds of selection had produced a virus with decreased sensitivity to the plasma’s 
neutralization activity (Figure 27A).  Envelope sequences were amplified from cellular 
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DNA and ten clones were sequenced in order to identify putative escape mutations.  A 
point mutation in variable loop three (V3) of GP120, K306E, was common to all 
sequenced clones (Figure 28).  An envelope gene that did not contain any changes other 
than K306E was subcloned into the parental virus and a titration of neutralizing plasma 
demonstrated that this single mutation entirely recapitulated the decreased sensitivity 
observed in the bulk population of passaged virus (Figure 27A).   
 The V3 loop has previously been identified as a target of neutralizing antibody 
binding, but mutations to the V3 loop have also been implicated in conformational 
changes that shift the general neutralization sensitivity of GP120.   Specifically, a gain of 
positive charges, particularly in residues 306 and 320, are thought to “open” the 
conformation of GP120, which allows a shift in co-receptor usage from CCR5 to 
CXCR4; but this conformational change is thought to also render the virus more 
neutralization sensitive (54, 55).  Here, the starting virus was X4-tropic and it is possible 
that the K306E is not a specific antigen binding-site mutation that emerged due to escape 
from recognition by a particular antibody, but rather it may have caused a conformational 
change that was generally protective against a variety of antibodies.  Although MT2 cells 
do not express CCR5, K306E was still tested for its ability to utilize it as a co-receptor to 
determine if the virus collaterally gained dual-tropism during neutralization escape.  
Infection of CHO cells expressing a humanized cyclin-T (to allow HIV transcription), 
human CD4, and either human CCR5 or human CXCR4 (259) showed that K306E was 
still only X4-tropic (Figure 27B).  Nevertheless, the emergence of a residue associated 
with R5-tropism during neutralizing antibody escape, supports a model in which residues 
associated with X4-tropism are inherently more neutralization sensitive. 
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Figure 26.  Selection using patient blood plasma with virus-neutralizing activity.  A) MT2 cells 
were infected with clonal Vif+ virus at MOI 0.001.  The following day, infected cells were split 
into plain media, or two-fold serial dilutions of patient plasma.  Fresh plasma was added at the 
same dilution when cells were split every four days.  B) Second Passage.  MT2 cells were 
infected with virus selected in a 1:20 dilution of plasma (from A) or the same virus used to 
initiate the first passage, both at MOI 0.001.  The next day, both infection were split into plain 
media or media containing a 1:20 patient blood plasma dilution.   
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Figure 27.  Escape mutants show decreased sensitivity to neutralization and remain X4-tropic.  A) 
HIV-1 used to initiate plasma selection (wt), virus resulting from two rounds of selection with a 
1:20 dilution of plasma (post-selection), or virus containing a lysine to glutamate mutation at 
envelope residue 306 (K306E) were used to infect TZM cells in the presence of neutralizing 
plasma at the indicated dilutions.   As was done for drug titrations in TZM cells, infection was 
quantified two d.p.i. in relative luminescence units by a luciferase activity assay.  Inhibition 
relative to a minus-plasma control (%) is plotted verses plasma dilution.  B) HIV-1 GFP 
containing the R5-tropic YU2 envelope, the X4-tropic HXB-2 envelope, or HXB-2 envelope with 
the K306E mutation was used to infect 10
4
 HIV-1 permissive CHO cell lines expressing either 
human CCR5 or human CXCR4.  An average of two infections is shown for each.   
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Figure 28.  A V3 loop mutation was fixed into viral population during selection by neutralizing 
plasma.  Proviral envelope sequences amplified from MT2 cells after two rounds of selection in 
neutralizing plasma were aligned with a confirmed wildtype HIV-1 HXB envelope sequence.  
Blue lines mark the boundaries of the V3 loop and the K306E mutation is indicated with an 
asterisk.   
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Chapter V.  Identification of the CERV2 cell surface receptor 
 
 
 While it remains possible that, as a means of defense, APOBEC3 proteins were 
able to assault CERV1 and CERV2, the exploitation of other host factors by these viruses 
would have been crucial to their successful infection of primate ancestors.  In order to 
bind and enter cells, CERV1 and CERV2 had to hijack host proteins that normally reside 
on the cell surface to perform a task for the host.  It is likely that the identity of these 
receptors determined the types of cells that CERV1 and CERV2 were able to enter and, 
perhaps, even the range of species they were capable of infecting.  Therefore, to 
understand the ancient inter-species transmissions and endogenizations of CERV1 and 
CERV2, it is necessary to identify their cell-surface receptors.  
 In order to study the host range and receptor usage of CERV1 and CERV2 during 
the time that they replicated, we constructed consensus envelope genes from both virus 
families.  Figure 29 shows an alignment of CERV2, RhERV2, and CERV1 consensus 
envelopes with moloney MLV envelope.  As is common for gammaretroviral envelopes, 
a high degree of conservation was observed in the transmembrane protein (TM also 
known as p12E) compared to a divergent surface protein (SU also know as gp70).  As 
expected, sequences were especially divergent in the regions that are responsible for 
receptor binding in MLV (variable regions A and B); with the exception of CERV2 and 
RhERV2, whose conservation in these regions may predict a common receptor usage.   
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Figure 29.  Clustal alignment of envelope protein sequences.  Majority consensus 
sequences of CERV2 envelope, RhERV2 envelopes A and B, and CERV1 envelope are 
aligned with the moloney murine leukemia virus (moMLV) ecotropic envelope. The first 
and last residues of the mature surface protein (SU or gp70) and transmembrane protein 
(TM or p12E) are marked with red and blue asterisks, respectively.  Proceeding SU is the 
cleaved signal peptide and following TM is the R-peptide (or p2E). Variable regions A 
and B are indicated by brackets according to those defined for MLV envelopes. 
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 Using CERV2 enveloped MLV pseudotypes carrying a GFP reporter (MLV-
GFP), it was determined that the consensus CERV2 envelope was functional (Figure 
30A).  Furthermore, it displayed a broad species tropism in that it supported infection of 
human, chimpanzee, rhesus macaque, African green monkey, owl monkey, dog, rat, and 
mouse cell lines.  The permissivity of HeLa cells for CERV2 infection validated the use 
of a HeLa cDNA library in a genetic screen for a CERV2 receptor, while the non-
permissive CHO-PGSA cells provided a negative background in which to perform such a 
screen.  CERV1 enveloped MLV particles were also able to infect both human and rhesus 
macaque cells, but their low infectious titer prevented any practical genetic screen for a 
CERV1 receptor (Figure 30C).  Importantly, the ability of CERV1 and CERV2 
enveloped particles to infect human cells already argues against the notion that the 
absence of functional receptors protected the human lineage from CERV1 and CERV2 
infection. 
 In order to identify the receptor used by CERV2 during the time of its exogenous 
replication, a HeLa cDNA cell expression library was screened using particles that 
carried the resurrected CERV2 envelope.   First, VSV-G enveloped MLV particles were 
used to stably transduce CHO-PGSA cells, which are normally resistant to CERV2 
infection, with the HeLa cDNA library.  The cDNA was delivered with an MLV vector 
and 3’ to the cloning site, an internal ribosomal entry site (IRES) drove the expression of 
a zeocin resistance gene.  Transduction with the cDNA library was done in 20 parallel 
pools of 2X10
5
 cells at an MOI of 0.5.  Following zeocin selection, 10
5
 cells from each 
PGSA cell expression library were challenged in duplicate with CERV2-enveloped 
virions carrying a neomycin-resistant gene.  This was done at a maximal MOI (3.5) to 
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insure redundant coverage of every transduced PGSA clone.  All but one of the forty 
independent infections yielded neomycin-resistant colonies ranging in number from one 
to twenty-four (Table 2).  The colonies were pooled into 20 separate groups according to 
the 20 initial cell expression sub-libraries.  Each of these neomycin-resistant pools was 
challenged independently with CERV2-enveloped virions carrying a hygromycin-
resistant gene.  Numerous hygromycin resistant cells readily grew out of three of the 
twenty pools.  When challenged with CERV2-enveloped MLV virions that carried a 
DsRED reporter gene, the hygromycin-resistant cells displayed a 100-fold increase in 
permissivity relative to unmanipulated CHO-PGSA cells.  Furthermore, this increase in 
CERV2 permissivity occurred without a change in resistance to amphotropic MLV 
infection (Figure 30B). 
 PCR amplification was performed using genomic DNA from the three PGSA cell 
lines permissive to CERV2 infection (Figure 30D).  To amplify the transduced gene(s), 
primers were designed to bind sequences flanking the cloning site in the vector used to 
deliver the HeLa cDNA library.  A 1.7kb PCR product, which was not amplified when 
DNA from unmanipulated PGSA was used, was cloned from all three cell lines and 
identified by sequence homology to encode human copper transport protein 1 (CTR1) 
(296).  By comparison to database cDNA sequence, it was clear that all three clones were 
missing the same number nucleotides from the end of the 5’ untranslated region, 
implying that the three copies of Ctr1 isolated independently in the screen represented a 
single molecular clone in the cDNA library that was transduced into PGSA cells three 
independent times, each in a separate pool of starting PGSA cells.
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Table 2.  Number of neomycin-resistant colonies 
from CERV2-challenged CHO-PGSA cell 
expression libraries. 
 
Neomycin selection was applied following challenge with 
CERV2 enveloped MLV virions.  Results from two 
replicate infections of each pool are shown. 
 
  
 In order to confirm that CTR1 expression was sufficient to confer CERV2 
sensitivity to CHO-PGSA cells, the coding region was stably transduced into both PGSA 
and the parental CHO cell line.  The Ctr1 open reading frame was amplified using a 
plasmid containing Ctr1 cDNA and the product was cloned into an MLV vector.  VSV-G 
enveloped MLV particles were used to transduce CHO and CHO-PGSA with both the 
CTR1 open reading frame and a neomycin resistance gene.   Indeed, expression of CTR1 
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in both CHO and CHO-PGSA cells resulted in permissivity to CERV2 enveloped MLV 
(Figures 30B,C).  Expression of human CTR1 also made CHO cells permissive to an 
MLV pseudotype carrying a consensus envelope from the CERV2 homologue in the 
rhesus macaque genome (RhERV2).  In contrast, transduction of human CTR1 did make 
CHO cells permissive to CERV1, MPMV, GALV, or amphotropic MLV enveloped 
virions, providing evidence that human CTR1 specifically enhances sensitivity to 
CERV2.  
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Figure 30.  Human CTR-1 is sufficient to confer permissivity to CERV2 env mediated 
entry in hamster cells.  A) 50!L of CERV2-enveloped MLV particles carrying a GFP 
reporter were used to infect 10
4
 cells.  Cell lines from a variety of species were used- 
human (293T, Hela), chimpanzee (PTSF), rhesus macaque (FRHK), African green 
monkey (COS7), owl monkey (OMK), dog (D17), cat (CRFK), pig (PK15), rat (Rat2), 
mouse (MDTF), and hamster (PGSA).  Cells were analyzed by FACS two days after 
infection.  B) Following two rounds of selection with CERV2 enveloped MLV 
pseudotypes, cells from three separate pools of cDNA library transduced CHO-PGSA 
were tested for CERV2 permissivity compared to un-manipulated cells.  MLV particles 
carrying the indicated envelope and DsRED reporter construct were used to infect cells as 
in A.  CHO-PGSA stably transduced with human CTR1 were included in subsequent 
replicates.  C) CHO, CHO stably transduced with human CTR1, 293T, and FRHK were 
infected as in A and B with MLV-GFP reporter virus pseudotyped with the indicated 
envelope.  D) DNA from three different CHO-PGSA cell lines, shown in (B) to be 
permissive to CERV2, or unmanipulated CHO-PGSA were used in PCRs with primers 
designed to amplify transduced HeLa cDNAs.  PCR products were resolved on an 
agarose gel.  A 1.7kb product (indicated with an arrow) was common to PCRs from all 
cell lines except unmanipulated CHO-PGSA. 
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CERV2 entry into primate cells requires CTR1 and occurs at the plasma 
membrane 
 Next, we asked if CTR1 is necessary in human cells for CERV2 infection.  Two 
different human cells lines were transfected twice with an siRNA pool targeting the 
human Ctr1 open reading frame or luciferase siRNA and then re-plated for infection.  
CTR1 siRNA pool was validated independently by knockdown of tagged CTR1 
ectopically expressed in 293T cells (Figure 31A).  Transfection of siRNAs against CTR1 
reduced CERV2 infection by up to three-fold compared to cells transfected with control 
siRNA, while susceptibility to amphotropic or VSV-G enveloped MLV was unaffected 
(Figure 31B).  To further demonstrate the necessity of CTR1 in CERV2 infections, we 
tested whether its normal ligand, copper, is capable of inhibiting its function as a viral 
receptor.  Copper II chloride treatment did in fact cause a dose-dependent decrease in 
HeLa infection that was specific for CERV2 enveloped virions (Figure 31C).   
 It has been shown that ectopically expressed CTR1 is endocytosed in response to 
increased copper concentrations (297).  In order to ask whether endocytosis, followed by 
lysosomal maturation is involved in CERV2 entry, we determined if CERV2 infection is 
pH-dependent.  Pre-treatment and infection in the presence of either ammonium chloride 
or the lysosomal maturation inhibitor, bafilomycin-A demonstrated in CHO-hCTR1 and 
TE671 that infection by CERV2 enveloped MLV is a pH-independent event (Figure 32). 
 119 
Figure 31.  CTR1 is necessary for CERV2 infection in human cells.  A and B) 293T or HT1080 
cells were transfected twice with an siRNA pool targeting CTR1 or luciferase siRNA before 
seeding for infection with MLV-GFP carrying CERV2 or amphotropic envelope.  Separately, 
293T cells were co-transfected with plasmid expressing human CTR1 with an N-terminal HA tag.  
Western blots from these cells are shown in A.  Glycosylated forms of CTR1 can be observed 
above the un-glycosylated protein (298-300).  C) HeLa cells were incubated for 2 hours in CuCl2 
before infection at the same CuCl2 concentration with the indicated MLV-GFP pseudotype.  After 
overnight incubation, cells were washed with fresh media and FACs analysis was completed 2 
days after infection. 
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Figure 32.  CERV2 entry is pH-independent.  TE671 (A) or CHO-huCTR1 (B) cells were 
infected by CERV2, amphotropic, or VSV enveloped MLV-GFP +/- 30mM NH4Cl or 25nM 
bafilomycin A following a two-hour pre-incubation under the same condition.  After 3 hours of 
infection, virus was removed and cells were incubated for an additional 2 hours in fresh media 
with 30mM NH4Cl or 25nM bafilomycin A before replacement with plain media.   
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Figure 33.  Human CTR1 promotes binding of CERV2 particles to CHO cells.  MLV Gag-
GFP particles with or without CERV2 envelope were bound to CHO or a CHO-
humanCTR1 single-cell clone.  After one hour, cells were washed, fixed, and stained with 
DAPI for microscopy.  In parallel, CERV2 particle binding was also done in the presence 
of CuCl2 following a CuCl2 pre-incubation.  Images of CERV2 particles bound to each of 
the cell types are shown including a merge of fluorescence with phase contrast.  For 
quantitation, 15 cells from each condition were chosen at random and the number of GFP 
particles per cell was counted. The mean is indicated by a bar. 
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CTR1 induces binding of CERV2 to the plasma membrane 
 To visualize virus attachment to target cells, an MLV Gag was used that carried a 
C-terminal GFP fusion.  Plasmid encoding the MLV Gag-GFP was transfected either 
alone or with plasmid expressing the CERV2 envelope.  This resulted in the production 
of GFP-labeled virions that either carried CERV2 envelope or lacked an envelope 
glycoprotein.  Particles were bound to CHO cells or a CHO single-cell clone expressing 
human CTR1 by applying un-concentrated supernatent at 4°C.  Following a one-hour 
incubation with the labeled virions, cells were washed three times and then fixed for 
microscopy.  Binding of CERV2 enveloped virions to unmanipulated CHO cells, in terms 
of the average number of GFP foci per cell, was seen only at a very low level- lower even 
than non-specific binding by particles lacking envelope glycoprotein (Figure 33B).  On 
the other hand, numerous CERV2 enveloped particles were bound to CHO-CTR1 cells 
(Figures 33A, B).  There were four times more CERV2 particles bound to CHO-CTR1 
compared to CHO, and expression of human CTR1 did not have an effect on the binding 
of non-enveloped virions.  This demonstrates that human CTR1 is able to confer CHO 
cells with the ability to bind CERV2 virions.   
 To further demonstrate that CTR1 is the cellular receptor for CERV2, we asked if 
excessive copper decreases virion binding to cells (Figure 33B).  CHO or CHO-CTR1 
cells were pre-treated with 20!M CuCl2 followed by binding with CERV2-enveloped 
GFP-labeled virions in the presence of 20uM CuCl2.  Treatment with CuCl2 caused an 
approximately two-fold decrease in the average number of CERV2 virions bound to 
CHO-CTR1.  This effect was modest compared to the 10-fold effect that 20uM CuCl2 had 
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on HeLa infection.  Therefore, it is likely that the binding defect does not entirely explain 
the effect that copper treatment has on CERV2 infection and, perhaps, excessive copper 
can also perturb events downstream of CTR1 binding. 
 
Genetic determinants of CTR1 receptor function 
 To determine if the use of CTR1 by CERV2 is directly related to its cellular 
function, mutants that have been previously shown to be deficient in copper transport 
were tested for viral receptor function.  Two CTR1 mutants with single amino acid 
changes that were previously shown to have an effect on the rate of copper uptake were 
included: M81I and Y156A (301).  A third included point mutation, C189S, has been 
shown to decrease CTR1 trimer stability (298).  None of these point mutations affected 
the ability of human CTR1 to serve as a CERV2 receptor (Figure 34B).  Therefore, the 
ability of CTR1 to serve as a receptor for CERV2 can be uncoupled from its copper 
transport function.   
 Next, we sought to identify the genetic determinants of CTR1 viral receptor 
function that render hamster cells non-permissive, and human cells permissive to CERV2 
infection.  Stable transduction of CHO cells with hamster CTR1 did not confer CERV2 
permissivity, suggesting that the lack of CERV2 infection in unmanipulated CHO cells 
was not merely due to low endogenous CTR1 expression (Figure 34A).  CTR1 has three 
transmembrane domains with a 64 amino acid extracellular N-terminal domain and a 
three amino acid extracellular loop (298, 299, 302).  To investigate whether the N-
terminal extracellular domain from human CTR1 is both sufficient to confer viral 
receptor activity to hamster CTR1 and necessary for the viral receptor function of human 
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CTR1, this domain was swapped between the human and hamster genes and the resulting 
chimeras were transduced into CHO cells.  CHO cells stably expressing a hamster CTR1 
with the human N-terminal extracellular domain were as permissive to CERV2 as CHO 
cells expressing the full-length human CTR1, whereas CHO cells expressing human 
CTR1 with the hamster N-terminal extracellular domain were non-permissive to CERV2 
(Figure 34A).  A C-terminal HA tag was included with the human, hamster, and chimeric 
CTR1 proteins and a western blot demonstrated that all four cell lines had comparable 
levels of CTR1 expression (Figure 34A insert).    
 Alignment of CTR1 amino acid sequences from primates revealed a high degree 
of conservation (Figure 35).  CTR1 proteins from human and chimpanzee are identical 
and, relative to this amino acid sequence, the rhesus macaque CTR1 has two amino acid 
differences and the orangutan, only one.  All three of these mutations are found within 
the N-terminal area of the extracellular domain that precedes an essential MMMMPM 
copper coordination motif (303).  An alignment of CTR1 from a wide range of mammals, 
frog, and zebrafish shows broad divergence in this 40 amino acid N-terminal region, 
which is followed by a highly conserved sequence in the rest of the protein.  Transduction 
of CHO cells with either wildtype human CTR1 or a mutant with a 40 amino acid N-
terminal truncation was able to induce CERV2 permissivity to a similar degree (Figure 
34B).  The ability of CERV2 to use the CTR1 truncation mutant as a receptor 
demonstrated that the most divergent region of CTR1 is dispensable in its receptor 
function.  As was therefore expected, hamster CTR1 mutants that resembled human 
CTR1 in the membrane proximal portion of the extracellular domain were competent as 
CERV2 receptors.  Specifically, stable expression of a hamster CTR1 that contained the 
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R(53)N and Y(59)S mutations (numbered by homology to human CTR1) was able to 
induce CERV2 susceptibility in CHO cells.  Furthermore, the addition of three 
methionines to form a MMMMXM motif improved the receptor function of the 
R(53)N/Y(59)S hamster CTR1 mutant.  Inversely, a three-methionine deletion in the 
human CTR1 MMMMXM motif resulted in decreased receptor activity and the 
N53R/S59Y human CTR1 double mutant did not display any receptor function in CHO 
cells.  An N-terminal HA tag was included in all CTR1 proteins tested and expression in 
transduced CHO cells was confirmed by western blot and surface stains (Figure 34B 
insert and Table 3).  Both the human CTR1 mutant containing a three-methionine 
deletion and the N53R/S59Y double mutant had lower expression levels in CHO cells 
compared to the wildtype human CTR1.  It is possible that these expression differences 
partially explain their lack of receptor activity.  Nevertheless, the gain of receptor 
function induced by the reciprocal mutations in hamster CTR1 clearly demonstrates the 
importance of these residues in CERV2 infection.   
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Figure 34.  Genetic determinants of CTR1 viral receptor function.  A) CHO cell lines expressing 
C-terminal HA tagged human CTR1 (Hu), hamster CTR1 (Ham) or N-terminal extracellular 
domain swaps (Hu-Ham and Ham-Hu) were seeded for infection with MLV-GFP pseudotypes. 
Expression of CTR1 was detected by "HA western blot, and the glycosylated band is shown to 
the right.  B) CHO cells expressing N-terminal HA tagged CTR1 were infected with CERV2 
enveloped MLV-GFP or used for "HA western blot (shown on right).  Mutations to human CTR1 
(wt) or hamster CTR1 (hamster wt) are indicated including a deletion of 40 amino acids at the N-
terminus (40del) of human CTR1, deletion of methionine residues 41-43 (3Mdel) in human 
CTR1, or addition of three methionine residues at the orthologous position in hamster CTR1 
(ham 3Madd). 
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Table 3.  Surface staining of CHO 
cells expressing N-terminal HA 
tagged CTR1. 
CHO cell lines MFI %cells + 
wt human CTR1 161 62.5 
40del 154 84.4 
M81I 324 94.4 
Y156A 107 41.2 
C189S 339 27.9 
3Mdel 109 37.5 
S59Y 342 79.0 
N53R/S59S 92 40.0 
wt hamster CTR1 160 73.9 
ham 3Madd 92 45.8 
ham R(53)N 135 58.3 
ham Y(59)S 153 63.3 
ham R(53)N/Y(59)S 125 52.4 
ham 3Madd/R(53)N/Y(59)S 203 78.0 
LNCX2 9 1.2 
wt human CTR1 unstained 3 0.5 
Stains were done with a mouse "HA 
monoclonal antibody and an AlexaFluor488 
conjugated secondary antibody before 
FACS analysis.  Mean fluorescence 
intensity (MFI) of the entire population and 
the %cells with fluorescence greater than 
that of vector and unstained controls is 
shown. 
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Figure 35.  Clustal alignment of CTR1 proteins.  The MMMMXM copper-coordination motif is 
marked by a copper colored box, transmembrane domains by blue boxes, and residues mutated 
for the studies herein are indicated by asterisks.  The hamster CTR1 sequence was determined by 
cloning the gene from CHO cDNA.  All other sequences were previously annotated in the NCBI 
gene database or were collected by a TBLASTN search of the non-redundant nucleotide database.  
Sequences from chimpanzee, rhesus macaque, horse, dog, platypus, and opossum are annotated in 
the sequence database as predicted transcripts.  In the case of dog CTR1, a start codon at a 
position homologous to other species is lacking therefore a downstream hypothetical start codon 
(proceeding a G nucleotide) is shown.     
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Chapter VI.  Discussion  
 
 
 The study of contemporary viruses can describe modern, but not necessarily 
formative, interactions between host genes and pathogens.  The existence of endogenous 
retroviral relics in host genomes allows for explorations of host and retrovirus co-
evolution that are not limited to present day infectious agents.  The work herein 
endeavored to gather evidence for or against past encounters of host factors with viruses 
that have not replicated exogenously for millions of years, but may have imposed positive 
selection on primate genes.  The peculiar absence of CERV1 and CERV2 from the 
human genome made them intriguing subjects for such studies because restrictions to 
their exogenous replication by antiviral proteins may have limited their host ranges or 
even caused their extinction.   
 Our investigation began with TRIM5 and APOBEC3 proteins because their 
ability to restrict modern MLV set a reasonable precedent for the hypothesis that they 
were also capable of targeting archaic primate gammaretroviruses (109, 110, 160, 304).  
Evidence argued against the role of TRIM5" proteins, though, in both the inactivation of 
CERV1 and CERV2 and in broad restrictions to their cross-species transmissions.  
Nearly all endogenous capsid N-terminal domains studied lacked sensitivity to TRIM5 
proteins from a variety of primate species.  RhERV2 capsids carrying an E91K mutation 
were an exception to the general TRIM5 resistance displayed by all other endogenous 
retroviral capsids.  Virions carrying these particular RhERV2 capsids were restricted by 
chimpanzee TRIM5" and marginally by human TRIM5".  The abundance of 91K in 
 131 
RhERV2 capsids (~20%) and its complete absence in CERV2 suggests that TRIM5" 
may have imposed a selective pressure that limited the cross-species transmission of 
viruses carrying this particular mutation to the chimpanzee ancestor and/or imposed a 
constraint on CERV2 capsid variability.   
 There are two possible caveats to this study.  First, the inactivation of CERV1/2 
viruses, and hence the end of any possible selective pressure imposed by these 
retroviruses on TRIM5 genes, may have occurred early enough in evolutionary history to 
allow genetic drift and/or further selection by more recent pathogens to cause a loss in 
recognition of ancient capsids by TRIM5 proteins.  In other words, neutral evolution or 
positive selection imposed by viruses other than CERV1/2 may have caused TRIM5 
proteins to lose CERV1/2 capsid recognition.  Contrary to this argument, though, is the 
high degree of functional conservation and sequence identity between human and 
chimpanzee TRIM5": 97% by amino acid sequence.  Since the replication of CERV1/2 
occurred after the divergence of humans and chimpanzees six million years ago, any 
recent changes in TRIM5 specificity caused by the rise and fall of species-specific 
retroviruses should be reflected in the divergence of these two genes; but despite the 
absence of CERV1/2 from the human genome and its presence in the chimpanzee, 
TRIM5" remains heavily conserved in both sequence and functional terms in these two 
species.  Furthermore, there are polymorphisms that remain common to both the rhesus 
macaque and the sooty mangabey despite geographic separation and eight million years 
of divergence, which suggests that balancing selection has prevented primate TRIM5" 
from significantly shifting during the last few million years (305).  In short, it is likely 
that the replication of CERV1/2 and their homologues is too recent relative TRIM5 
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functional divergence for changes in TRIM5" specificity to pose a problem in the 
experiments discussed here. 
 Second, it is possible that there are unknown determinants of TRIM sensitivity 
that are outside of the N-terminal domain of capsid.  This concern was especially 
highlighted by the description of a chimeric MLV containing p12 and a complete capsid 
protein of an ancestral CERV1 that was restricted by human and chimpanzee TRIM5" 
(260).  It seems unlikely that the inclusion of the CERV1 CA-CTD or the p12 domain 
could affect TRIM5 sensitivity because all known determinants of TRIM5 and Fv1 
sensitivity map to the CA-NTD (108-111, 113, 114), and cleavage from the p12 domain 
is required for MLV CA to interact with TRIM5 and Fv1 (306).  However, in order to 
deal with the possibility that there is an unknown determinant of TRIM5 recognition in 
the capsid C-terminal domain, ancestral and consensus CERV1 full-length capsids were 
used to confirm that chimeras carrying CERV1 capsid are resistant to TRIM5.  Thus, this 
result strongly supports the notion that TRIM5" proteins did not restrict CERV1 and it 
also validates our experimental strategy for testing a broader range of CA-NTDs for 
TRIM5 sensitivity.  
 Although it appears that TRIM5 proteins did not have an impact on CERV1 and 
CERV2 replication, evidence does suggest that these viruses encountered APOBEC3 
family member in both the chimpanzee and the rhesus macaque.  This is evidenced by a 
large number of G to A changes that occurred in dinucleotide contexts that are indicative 
of modern APOBEC3 proteins.  A disproportionate number of GG to AG mutations 
compared to other G to A mutations was documented in CERV1, CERV2, RhERV1a, 
RhERV2 and an excess of GA to AA mutations were also observed in individual 
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RhERV2 proviruses.   It is intriguing that RhERV2, unlike the other groups studied, 
displayed two distinct dinucleotide biases: both GG to AG and GA to AA mutations on 
separate proviruses.  It is unlikely that these two mutagenic activities were separated 
temporally because the proviruses in which they were found are not separated into two 
phylogentically distinct groups.  Rather, it is likely that RhERV2 was simultaneously 
subjected to the action of at least two different deaminases.  Indeed, modern rhesus 
APOBEC3F and APOBEC3H are highly active relative to their human orthologues, 
suggesting that they may be responsible for the abundant GA to AA mutations found in 
RhERV2 (155-158). 
 Several analyses were completed in order to confirm that the excessive G to A 
mutations in GG or GA dinucleotides were caused by APOBEC3-catalyzed deamination.  
By removing CG dinucleotides from our analyses, we confirmed that the GG to AG 
mutations observed were not due to spontaneous deamination at methylated CG islands in 
the context of CGG trinucleotides.  Some of the G to A mutations that were common to 
multiple proviruses may have been due to amplification of a relatively small number of G 
to A changes from founder viruses.  It is unlikely, though, that the GG to AG changes 
would be selectively amplified over other mutations because these changes did not confer 
any fitness advantage MLV chimeras containing CERV1/2 CA-NTDs.  To confirm that 
the dinucleotide biases observed extend outside of capsid, many of the results were 
corroborated by examining mutational biases in envelopes that were linked to the capsids 
analyzed.  Cases in which the bias in the G to A mutations was not consistent between a 
capsid and a linked envelope could be explained by (i) stochastic variation in the small 
numbers of capsid G to A mutations in th relatively short CA-NTD sequence (~400nt) (ii) 
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variation in the mutation frequency (including 5’ to 3’ gradients) across individual 
proviruses (iii) recombination between hypermutated and intact proviruses prior to or 
during germline invasion, and/or (iv) high degrees of general sequence diversity in some 
viral genes that may mask low frequency APOBEC3-mediated editing.    
 Modern APOBEC3G is known to induce GG to AG mutations but it remained 
possible that an un-characterized cytidine deaminase activity was responsible for these 
mutagenic events in CERV1 and CERV2.  Furthermore, direct evidence that the editing 
observed in these viruses translated to an observable restriction was lacking.  To address 
this, it was demonstrated in vitro that APOBEC3G can, in fact, restrict MLV chimeras 
carrying CERV2 Gag.  This supports the assertion that APOBEC3G was responsible for 
GG to AG mutation found in CERV2 and that this activity was capable of restricting 
CERV2 replication. 
 APOBEC3-induced mutations often crippled individual CERV1 and CERV2 
viruses through the frequent introduction of stop codons and other deleterious 
nonsynonomous changes.  Especially given high frequency of stop codons generated by 
GG to AG mutations, it is possible that APOBEC3 activity resulted in genetic loads that 
had a damaging impact on the viral populations within each infected individual and 
therefore may have also decreased the likelihood of intra- and interspecies transmissions.  
Especially given the in vitro results confirming that APOBEC3G is able to restrict the 
replication of virions containing CERV2 Gag , it is possible that APOBEC3 genes were 
able to limit the species tropism of CERV1 and CERV2.  Indeed, the species-specificity 
of APOBEC3 recognition by lentiviral Vif proteins at least partially explains the species 
tropism of modern lentiviruses; thus demonstrating the potential for APOBEC3 proteins 
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to impose transmission barriers (156, 175, 307).  in vitro APOBEC3G restriction assays, 
though, were unable to provide direct evidence for a species-specific difference in 
APOBEC3G potency against CERV2.  Specifically, virions containing CERV2 Gag were 
not more sensitive to human APOBEC3G compared to chimpanzee APOBEC3G, which 
was apparently not potent enough to prevent CERV2 endogenization in the chimpanzee 
ancestor.  
 It remains possible that the APOBEC3 activity described here was responsible for 
terminating CERV1/2 replication.  Again, deleterious non-synonymous mutations, 
particularly stop codon formation, likely constituted a genetic load capable of impairing 
the replication of a viral population within an infected host.  An assertion that these 
genetic loads caused CERV1/2 extinction may be premature, though, given that it is not 
known if the level of mutations observed in CERV1/2 constitute a burden that was too 
great for the viruses to overcome.  It has long been theorized that recombination evolved, 
in part, as a means to rid genomes of deleterious mutations, thus avoiding Muller’s 
ratchet and preventing mutational meltdown (204-207).  CERV1/2 may have been able to 
cope with the heavy mutational burden observed here by continually producing fit viruses 
through the recombination of mutated sequences.  It should also be stated that the 
proportion of proviruses in the infected chimpanzee and rhesus macaque ancestors that 
were hypermutated would be over-represented if a selection existed against the 
endogenization of fit viruses.  Overall, although APOBEC3 activity likely explains the 
inactivity of many individual CERV1/2 proviruses, it may or may not have contributed to 
the extinction of exogenous CERV1/2.   
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 Further study of the CERV2 host range, as well as the limitations that hosts may 
have imposed on it throughout history, required the identification of its cellular receptor.  
By resurrecting a functional CERV2 envelope, we have determined that CERV2 used 
CTR1 as its cell surface receptor during its exogenous replication millions of years ago.  
Human CTR1 expression was sufficient to allow CERV2 virion binding and infection in 
otherwise resistant hamster cells.  In human cells, siRNAs directed against CTR1 
inhibited CERV2 infection.  The remaining infection in CTR1 knockdown cells could be 
due to an incomplete knockdown but we cannot exclude the existence of a second 
CERV2 receptor.  The large effect that CuCl2 treatment had on CERV2 infection further 
supports the importance of CTR1 in the infection of human cells.  Although potent 
inhibition by CuCl2 was clearly specific for the CERV2 receptor, the exact mechanism is 
unclear.  Down-regulation of ectopically expressed CTR1 from the cell surface in 
response to CuCl2 treatment has been observed but it has also been shown that there is no 
such effect on endogenously expressed CTR1, suggesting that inhibition of HeLa cell 
infection is not necessarily explained by a lack of CTR1 cell surface expression (308-
310).  Furthermore, the modesty of the binding defect caused by CuCl2 suggests that 
perturbation of events downstream of initial binding to CTR1 may contribute to the 
inhibitory effect that copper treatment had on infection.  It is reasonable to speculate that 
high amounts of copper flux at or near sites of virion binding may interfere with proper 
virus attachment and/or fusion with the cell.   
 Several &-retroviruses use multi-transmembrane transport molecules as cell-
surface receptors.  Aside from their expression on the cell surface, no common property 
of transport proteins has been shown to promote their ability to serve as receptors for 
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viruses.  In the case of CTR1, we demonstrated that viral receptor activity could be 
uncoupled from its normal cellular function. Methionine residues are primarily 
responsible for copper ion coordination during uptake through the membrane pore 
formed by trimerized CTR1 (302, 303, 311).  Mutation at methionine 81 within the first 
transmembrane domain has been demonstrated to result in a two-fold decrease in the 
Vmax of copper uptake (301).  It has been suggested that tyrosine 156, found in the three-
residue extracellular loop, is responsible for positioning methionine residues at the 
exterior opening of the transport pore through hydrogen bonding and mutation at this 
residue results in a five-fold loss in copper uptake (301).  The observation that point 
mutants lacking each of these residues were able to serve as efficient viral receptors 
supports the view that, as has been shown for the ecotropic MLV receptor, solute 
transport function is not linked with virus reception (312).  
The ability of CERV2 to use human CTR1 suggests that a species-specific 
tropism during the period of exogenous CERV2 replication does not explain the absence 
of CERV2 from the human genome.  Additionally, human CTR1 is broadly expressed 
(313), which is to be expected given the use of copper ions by crucial cellular enzymes 
such as superoxide dismutase and cytochrome c oxidase.  In particular, the expression of 
CTR1 in the testes and ovaries implies that a lack of endogenization cannot be explained 
by the absence of receptor expression in the germ line.  Although we cannot rule out that 
human CTR1 has lost CERV2 resistance during the time since exogenous CERV2 
replication, this evolutionary course is unlikely given the perfect nucleotide sequence 
identity between the extra-cellular regions of human and chimpanzee CTR1.  Still, it 
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remains possible that CTR1 allelic variability once included CERV2 resistance and 
perhaps such polymorphisms were lost following the extinction of exogenous CERV2.   
Interestingly, nearly all of the CTR1 sequence diversity is found in its N-terminal 
extracellular domain and a 40 amino acid truncation mutant demonstrated that the area 
containing nearly all of this diversity is dispensable for virus receptor function (Figures 
34 and 35).  That CERV2 only requires the extracellular domain’s most conserved 
portion likely explains the permissivity of cells from diverse species.  Furthermore, it is 
possible that binding to this conserved region has been selected by multiple cross-species 
transmission events that favored binding to a region in the new host that is similar to that 
used by the virus in the previous host.  For sequence variability to dictate the portion of 
the receptor that was required for CERV2 infection, the virus would have to be capable of 
altering its receptor usage when faced with unfavorable residues on CTR1.  Observed 
differences in receptor utilization that exist between closely related gammaretroviruses 
suggests that they are, indeed, capable of rapidly changing the way they interact with a 
single receptor in response to selective pressure imposed by the host.  For example, 
polytropic and xenotropic MLV bind to the same XPR1 domain and a few differences in 
the receptor binding regions of xenotropic envelope enable it to also bind to a second 
domain on XPR1 (78).  Also, following the transmission FeLV-A to a new host, FeLV-B 
or FeLV-C arise recurrently through either point mutations or recombination with 
endogenous retroviruses, thus resulting in a swift change to a new receptor utilization 
(86, 90).  
Functional flexibility in the same extracellular region of CTR1 that is dispensable 
for viral infection is not only suggested by diversity between species, but also by 
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mutagenesis data.  A human CTR1 mutant with a 34 amino acid N-terminal truncation 
has been shown to entirely retain its copper transport ability (301).  It was suggested that 
this portion is responsible for receiving copper from extracellular copper chaperones that 
are yet to be discovered, but the data presented here raises the question of whether CTR1 
divergence could have been due to selective pressure imposed by retroviruses.  The 
extracellular copper-binding residues that are the most crucial to CTR1 function were 
previously demonstrated to be the highly conserved MMMMXM motif (303), which 
begins one residue before the end of a portion of CTR1 that is dispensable for CERV2 
infection.  In contrast to the high degree of conservation of this motif from human to 
zebrafish, the hamster CTR1 has only an MPM in the orthologous position and, perhaps 
for compensation, contains several unique copper-coordinating residues in other areas of 
its extracellular domain (Figure 35).  We have demonstrated that the three-methionine 
deletion, along with point mutations at two other highly conserved residues, are 
responsible for the resistance of hamster cells to CERV2 infection.  It is tempting to 
speculate that these changes represent an escape of the hamster lineage from a CERV2 
relative.  Whether or not this was the case, the divergence seen in the rest of the hamster 
CTR1 N-terminal domain may compensate for its loss in the primary copper coordination 
motif, thus representing an evolutionary hurdle that a primate would have had to 
overcome to acquire CERV2 resistance by way of receptor evolution.  The work 
described here demonstrates that paleovirology has the potential to both identify novel 
host factors that were usurped by ancient pathogens, as well as indicate the limitations 
that hosts may have had in avoiding such exploitations by viral invaders. 
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If the human ancestors were unable to avoid CERV2 infection through changes in 
CTR1, then why were they spared from CERV2 endogenization?  Again, we cannot rule 
out a role for APOBEC3-mediated restriction in the protection of the human lineage from 
both CERV1 and CERV2.  But given the absence of clear species-specific differences in 
CERV2 restriction potency, such a conclusion would fail to explain why APOBEC3 was 
not also cable of protecting non-human primate ancestors from infection.  One would 
have to invoke a model in which resistance to CERV2 infection was evolved in ancient 
primates through selection on APOBEC3 genes by CERV2 and the inactive proviruses in 
the chimpanzee and rhesus macaque ancestors are the products of restrictions that 
occurred following APOBEC3 adaptation.  If replication competent CERV2 was 
pathogenic, then a record of proviruses that integrated prior to the emergence of 
APOBEC3-mediated hypermutation would be limited by selection against the 
endogenization of active proviruses.   
The above remarks must be stated with circumspection, though, given that the 
presence of hypermutated proviruses does not necessarily predict that a given viral 
population would be unable to replicate.  If we may draw analogies between the effects 
that APOBEC3 can have on distant retroviruses, the interactions that APOBEC3 proteins 
have with HIV-1 suggest that a virus capable of overcoming restriction through the use of 
an antagonist can still be subjected to hypermutation.  Although an accumulation of 
APOBEC3-mediated mutations can be observed in a portion of HIV-1 populations in vivo 
and in vitro, the virus is still able to persist and avoid a mutational meltdown.  In the in 
vitro experiments presented here, hypermutation was observed in a vast majority of 
sequences collected from deltaVif virus grown in restrictive cells.   Importantly, the virus 
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was able to persist in spite of the APOBEC3-induced genetic load that likely decreased 
fitness and was not able to contribute to drug escape.  In other words, heavy 
hypermutation can impair viral evolution, but it does not necessarily provide a general 
protection for the host or cause a mutational meltdown.  Furthermore, in the case of Vif+ 
HIV-1, the presence of a low level of APOBEC3 activity did not appear to hinder drug 
resistance evolution and may have even contributed to it.   
Although HIV-1 and CERV1/2 are very distant viruses, it may be a recurrent 
theme in APOBEC3 activity that hypermutation can occur even during the replication of 
a virus that is able to persist.  If this was the case for CERV1/2, then the endogenized 
hypermutants may represent a small portion of the proviruses that has been biased toward 
hypermutants by selection against the fixation of replication competent individuals.  
Given that endogenization is a rare event and may exclude a highly fit majority, perhaps 
the absence of CERV1/2 in the modern human genome does not necessarily suggest that 
human ancestors were spared from exogenous CERV1/2.  It may even be the case that 
polymorphic CERV1/2 integrations were lost due to population bottlenecks during 
human evolution.  This has been suggested for a single HERV-K integration that is 
identical in the gorilla and chimpanzee, while the orthologous locus in the human genome 
contains an intact pre-integration site (314).  It was argued that the integration occurred 
prior to the divergence of the gorilla lineage from the human and chimpanzee and 
remained polymorphic during the divergence of the human and chimpanzee lineages.  
The allele carrying the integrated provirus then became fixed in the chimpanzee lineage 
but, by chance, was lost from the human lineage as the allele containing the unperturbed 
pre-integration site became fixed.  The notion that endogenous retroviruses can remain 
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polymorphic for long periods of time is supported by the observation that two HERV-K 
insertions, HERV-K113 and 115, remain polymorphic in humans (315).  If CERV1/2 did 
infect human ancestors and endogenizations only occurred in a small proportion of 
individuals, than one could imagine the neutral loss of entire groups of polymorphic 
endogenous retroviruses to population bottlenecks.   
 Nevertheless, a definitive molecular explanation for the absence of CERV1/2 
from the human genome may still exist.  The CERV1 consensus envelope was not 
sufficiently functional to perform a genetic screen, but if an improved envelope were to 
be constructed then receptor identification would be worthwhile and could potentially 
account for a limited CERV1 host range.  Also, the tetherin restriction factor should be 
considered.  Although tetherin activity, unlike TRIM5", does not appear to depend on the 
specific recognition of viral proteins, perhaps an unknown tetherin antagonist was able to 
protect primate gammaretroviruses in a species-specific manner.  Another potential 
avenue of study ignored here is CERV1/2 LTR promoter function.  Perhaps the CERV1/2 
LTRs were unable to promote transcription in human ancestors.  ZFP809 has been 
identified as a murine zinc finger protein responsible for silencing the transcription of 
MLV in embryonic stem cells through the bridging of transcriptional repressors to the 
retroviral primer-binding site (316).  Perhaps similar activities have guarded the human 
lineage from gammaretroviruses.  In general, as host genes continue to be identified that 
either aid or inhibit retroviruses, the history of retroviral evolution may be further 
explored and it is clear that paleovirology will continue to describe the formative and 
longstanding evolutionary combat between retroviruses and their hosts. 
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